We are offering 1,610,679 shares of our common stock pursuant to this prospectus supplement and accompanying prospectus to certain institutional investors. Each share of common stock is being sold at a price per share equal to $4.5018.

We are also offering pre-funded warrants to purchase up to 610,679 shares of common stock (the “Pre-funded Warrants”) to each purchaser whose purchase of shares of common stock in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. The purchase price of each Pre-funded Warrant will be equal to the price per share at which shares of common stock are sold to the public in this offering, minus $0.01, and the exercise price of each Pre-funded Warrant will be $0.01 per share. This offering also relates to the shares of common stock issuable upon exercise of any Pre-funded Warrants sold in this offering. The Pre-funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-funded Warrants are exercised in full.

In a concurrent private placement, we are also selling to such investors warrants to purchase up to 1,666,019 shares of our common stock (the “Warrants”), exercisable for one share of our common stock at an exercise price of $4.9519 per share, and exercisable immediately upon issuance with a term of five (5) years from the date of issuance. The Warrants and the shares of our common stock issuable upon the exercise of the Warrants (the “Warrant Shares”) are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying prospectus.

There is no established public trading market for the Pre-funded Warrants and Warrants and we do not expect a market to develop. In addition, we do not intend to list the Pre-funded Warrants and Warrants on The Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.

Our common stock is traded on The Nasdaq Capital Market under the symbol “ENVB.” On January 11, 2021, the closing sale price of our common stock on The Nasdaq Capital Market was $4.87 per share.

This investment involves a high degree of risk. See “Risk Factors” on page S-8 of this prospectus supplement and any similar section contained in the accompanying prospectus and in the documents that are incorporated by reference herein and therein.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

Delivery of the shares of common stock to investors is expected to occur on or about January 14, 2021, subject to satisfaction of customary closing conditions.

Effective as of 4:02 pm Eastern Time on December 30, 2020, we filed an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of our common stock, at a ratio of one share for four shares. The net result of the reverse stock split was a 1-for-4 reverse stock split. All share and per share prices in this prospectus supplement have been adjusted to reflect the reverse stock split.

This document is part of the registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference, gives more general information, some of which may not apply to this offering. Generally, when we refer only to the “prospectus,” we are referring to both parts combined. This prospectus supplement may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus.

If information in this prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by reference that was filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. This prospectus supplement, the accompanying prospectus and the documents incorporated into each by reference include important information about us, the securities being offered and other information you should know before investing in our securities. You should also read and consider information in the documents we have referred you to in the section of this prospectus supplement and the accompanying prospectus entitled “Incorporation by Reference” and “Where You Can Find More Information” as well as any free writing prospectus provided in connection with this offering.

You should rely only on this prospectus supplement, the accompanying prospectus, and any free writing prospectus provided in connection with this offering and the information incorporated or deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide you with information that is in addition to or different from that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus, and any free writing prospectus provided in connection with this offering. If anyone provides you with different or inconsistent information, you should not rely on it. We are not offering to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus, or any free writing prospectus provided in connection with this offering is accurate as of any date other than as of the date of this prospectus supplement, the accompanying prospectus, or such free writing prospectus, as the case may be, or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates.

Unless the context otherwise indicates, references in this prospectus to “Enveric”, “we”, “our”, “us” and “the Company” refer, collectively, to Enveric Biosciences, Inc. and its subsidiaries.

No action is being taken in any jurisdiction outside the United States to permit a public offering of the securities or possession or distribution of this prospectus supplement, the accompanying prospectus, or any free writing prospectus provided in connection with this offering in that jurisdiction. Persons who come into possession of this prospectus supplement, the accompanying prospectus, or any free writing prospectus provided in connection with this offering in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus supplement, the accompanying prospectus, or any free writing prospectus provided in connection with this offering applicable to that jurisdiction. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

This prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus supplement and the accompanying prospectus, and in particular those factors referenced in the sections entitled “Risk Factors.”

This prospectus supplement and the accompanying prospectus contain forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Numerous factors could cause our actual results to differ materially from those described in forward-looking statements, including, among other things:

We have included important factors in the cautionary statements included in this prospectus supplement and the accompanying prospectus and the documents we incorporate by reference herein and therein, including from the Form S-4, particularly in the “Risk Factors” sections of these documents, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. No forward-looking statement is a guarantee of future performance.

You should read this prospectus supplement and the accompanying prospectus and the documents that we incorporate by reference herein and therein completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this prospectus supplement and the accompanying prospectus and the documents we incorporate by reference herein and therein represent our views as of the date of this prospectus supplement. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus supplement.

Investing in our securities involves a high degree of risk. In addition to the other information contained in this prospectus supplement to the accompanying prospectus and in the documents we incorporate by reference, you should carefully consider the risks discussed below and under the heading “Risk Factors” in the Form S-4 before making a decision about investing in our securities. The risks and uncertainties discussed below and in the Form S-4 are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If any of these risks occur, our business, financial condition and operating results could be harmed, the trading price of our common stock could decline and you could lose part or all of your investment.

If you purchase securities in this offering, you will suffer immediate dilution of your investment.

The offering price of our common stock in this offering is substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase securities in this offering, you will pay a price per share of our common stock that substantially exceeds our net tangible book value per share after giving effect to this offering. Based on an offering price of $4.5018 per share of our common stock, if you purchase securities in this offering, you will experience immediate dilution of $3.4218 per share , representing the difference between the offering price per share of our common stock and our pro forma as adjusted net tangible book value per share after giving effect to this offering, assuming exercise of all Pre-funded Warrants sold in this offering. Furthermore, if any of our outstanding options or warrants are exercised at prices below the offering price, or if we grant additional options or other awards under our equity incentive plans or issue additional warrants, you may experience further dilution of your investment. See the section entitled “Dilution” below for a more detailed illustration of the dilution you would incur if you participate in this offering.

Because we will have broad discretion and flexibility in how the net proceeds from this offering are used, we may use the net proceeds in ways in which you disagree.

We intend to use the net proceeds from this offering for working capital purposes. See “Use of Proceeds” on page S-10. We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.

You may experience future dilution as a result of future equity offerings and other issuances of our securities. In addition, this offering and future equity offerings and other issuances of our common stock or other securities may adversely affect the price of our common stock.

In order to raise additional capital, we may in the future offer additional shares of common stock or other securities convertible into or exchangeable for our common stock prices that may not be the same as the price per share in this offering. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of common stock or securities convertible into shares of common stock in future transactions may be higher or lower than the price per share in this offering. You will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our stock incentive programs. In addition, the sale of shares of common stock in this offering and any future sales of a substantial number of shares of common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares for sale will have on the market price of our common stock.

We expect to require additional capital in the future in order to develop our product candidates, which are in early stages of development. If we do not obtain any such additional financing, it may be difficult to effectively realize our long-term strategic goals and objectives.

Our current cash resources will not be sufficient to fund the development of our product candidates through all of the required clinical trials to receive regulatory approval and commercialization. If we cannot secure this additional funding when such funds are required, we may fail to develop our product candidates or be forced to forego certain strategic opportunities.

Any additional capital raised through the sale of equity or equity-backed securities may dilute our stockholders’ ownership percentages and could also result in a decrease in the market value of our equity securities.

The terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities then outstanding.

In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.

There is no established public trading market for the Pre-funded Warrants being offered in this offering.

There is no established public trading market for the Pre-funded Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the Pre-funded Warrants on any national securities exchange or other nationally recognized trading system, including Nasdaq Capital Market. Without an active market, the liquidity of the Pre-funded Warrants will be limited.

Except as otherwise provided in the Pre-funded Warrants, holders of Pre-funded Warrants purchased in this offering will have no rights as stockholders of common stock until such holders exercise their Pre-funded Warrants and acquire our common stock.

Except as otherwise provided in the Pre-funded Warrants, until holders of Pre-funded Warrants acquire our common stock upon exercise of the Pre-funded Warrants, holders of Pre-funded Warrants will have no rights with respect to our common stock underlying such Pre-funded Warrants. Upon exercise of the Pre-funded Warrants, the holders will be entitled to exercise the rights of a stockholder of our common stock only as to matters for which the record date occurs after the exercise date.

We estimate that the net proceeds from the sale of the securities offered under this prospectus supplement, after deducting estimated offering expenses payable by us, will be approximately $9 million, excluding the proceeds we may receive form the exercise of the Pre-funded Warrants issued in this offering and Warrants issued in the concurrent private placement.

We intend to use the net proceeds from the sale of the shares for working capital purposes. The amounts and timing of our use of proceeds will vary depending on a number of factors, including the amount of cash generated or used by our operations. As a result, we will retain broad discretion in the allocation of the net proceeds of this offering.

We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.

If you invest in our common stock (and/or pre-funded warrants) in this offering, your ownership interest will be diluted by the difference between the price per share you pay and the net tangible book value per share of our common stock immediately after this offering.

Our net tangible book value as of September 30, 2020, was approximately $(3,589,158), or $(0.63) per share of our common stock, based upon 5,737,001 shares of our common stock outstanding as of that date. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September 30, 2020. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.

Our pro forma net tangible book value as of September 30, 2020, was approximately $5,884,217, or $0.51 per share, after giving effect to (i) the Spin-Off; (ii) the Offer, whereby the Company issued 7,621,052 shares of common stock and 262,500 shares of Series B Preferred Stock that are convertible into 262,500 shares of common stock in exchange for 35,635,807 common shares of Jay Pharma (excluding the issuance of an aggregate of 3,262,907 shares of Series B Preferred Stock that are convertible into 3,262,907 shares of common stock issued in transactions related to the Offer); (iii) the conversion of indebtedness and the securities issued upon closing of a private placement made in connection with the Offer; (iv) the acquisition of intellectual property by Jay Pharma in exchange for 10,360,007 common shares of Jay Pharma.

After giving effect to the sale of 1,610,679 shares of our common stock in this offering at the price of $4.5018 per share and Pre-funded Warrants to purchase up to 610,679 shares of common stock, and after deducting the estimated offering expenses payable by us and assuming exercise of all Pre-funded Warrants in this offering, our pro forma as adjusted net tangible book value as of September 30, 2020, would have been approximately $14,884,217, or $1.08 per share. This represents an immediate increase in net tangible book value of $0.57 per share to existing stockholders and immediate dilution in net tangible book value of $3.4218 per share to new investors. The following table illustrates this dilution on a per share basis:

The foregoing discussion and table assumes (i) the exercise of all Pre-funded Warrants sold in this offering and (ii) no exercise of the Warrants to be issued in a concurrent private placement. To the extent that outstanding options or warrants are exercised, you may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

The above discussion and table as of September 30, 2020 are based upon, after giving effect to the adjustments set forth above, and excludes, as of that date:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and operating results together with our financial statements and related notes incorporated by reference into this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. See “Special Note Regarding Forward-Looking Statements.” Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” or in other parts of this prospectus or the documents incorporated by reference into this prospectus. Unless stated otherwise, references in this discussion and analysis to “us,” “we,” “our,” “Enveric” or our “Company” and similar terms refer to Enveric Biosciences, Inc., a Delaware corporation. References to “Ameri” refer to our Company prior to the Offer.

On December 30, 2020, pursuant to the previously announced the Tender Agreement, we completed the Offer to purchase all of the outstanding common shares of Jay Pharma for the number of shares of common stock of the Company, par value $0.01 per share or Series B Preferred Stock, as applicable, equal to the exchange ratio of 0.8849, and Jay Pharma became a wholly-owned subsidiary of the Company, on the terms and conditions set forth in the Tender Agreement. Following the effective time of the Offer, the Company changed the name of the Company from AMERI Holdings, Inc. to Enveric Biosciences, Inc. and effected a 1-for-4 reverse stock split of the issued and outstanding common stock. Immediately following completion of the Offer and the transactions contemplated in the Tender Agreement, but without giving effect to the issuance of the Series B Warrants to purchase 1,791,923 shares of common stock, (i) the former Jay Pharma equity holders (including certain investors in private placements that closed prior to the completion of the Offer) own approximately 82.3% of the Company; (ii) former Ameri equity holders own approximately 14.5% of the Company; and (iii) a financial advisor to Jay Pharma and Ameri owns approximately 3.2% of the Company.

On December 30, 2020, pursuant to the Ameri Share Purchase Agreement, Ameri consummated the Spin-Off and all of the issued and outstanding shares of Series A Preferred Stock were redeemed for an equal number of shares of Private Ameri Preferred Stock. Ameri contributed, transferred and conveyed to Private Ameri all of the issued and outstanding equity interests of the existing subsidiaries of Ameri, constituting the entire business and operations of Ameri and its subsidiaries, and Private Ameri assumed the liabilities of such subsidiaries.

The Offer has been accounted for as a “reverse merger” under the acquisition method of accounting for business combinations with Jay Pharma treated as the accounting acquirer of Ameri. As such, the historical financial statements of Jay Pharma have become the historical financial statements of Ameri, or the combined company, and are incorporated into this report labeled “Jay Pharma, Inc.” No historical common stock, stock options and additional paid-in capital, including share and per share amounts presented in this Management’s Discussion and Analysis of Financial Condition and Results of Operations has been adjusted to reflect the equity structure of the resulting issuer as a result of the Offer and the related transactions, including the effect of the Exchange Ratio and the common stock.

On December 30, 2020, we affected a 1-for-4 reverse stock split. We made proportionate adjustments to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, restricted stock units (if any) and warrants outstanding as of the effective times of the reverse stock split in accordance with the terms of each security based on the split ratio. Also, we reduced the number of shares reserved for issuance under our equity compensation plans proportionately based on the split ratios. Except for adjustments that resulted from the rounding up of fractional shares to the next whole share, the reverse stock split affected all stockholders uniformly and did not change any stockholder’s percentage ownership interest in our company. All share and related option and warrant information presented in this prospectus supplement (other than this Management’s Discussion and Analysis of Financial Condition and Results of Operations as noted below) have been retroactively adjusted to reflect the reduced number of shares outstanding and the increase in share price which resulted from these actions; however, common stock share and per share amounts in the accompanying prospectus and certain of the documents incorporated by reference herein have not been adjusted to give effect to the reverse stock split. No share or related option or warrant information presented in this Management’s Discussion and Analysis of Financial Condition and Results of Operations has been adjusted to reflect the reduced number of shares outstanding, the increase in share price which resulted from these actions or otherwise give effect to the reverse stock split.

We are a biopharmaceutical and wellness company that is seeking to develop innovative, evidence-based cannabinoid product candidates and combination therapies to address unmet needs in cancer care. We seek to improve the lives of persons suffering from cancer, initially by developing over-the-counter palliative cancer care and wellness cosmetic product candidates for persons suffering from the side effects of cancer and cancer treatment. We are also aiming to advance a pipeline of novel cannabinoid combination therapies for hard-to-treat cancers, including glioblastoma multiforme (GBM). We are to bring leading oncology clinicians and researchers, academic and industry partners, proprietary products and data, and eventually a robust pipeline of product candidates, to improve quality of life and provide symptomatic relief to cancer patients.

Our operating expenses include financial statement preparation services, tax compliance, various consulting and director fees, legal services, auditing fees, and stock-based compensation. These expenses have increased in connection with the Company’s product development and the Company’s management expects these expenses to continue to increase as the Company continues to develop its potential product candidates.

The following table sets forth information comparing the components of net loss for the nine months ended September 30, 2020 and the comparable period in 2019:

Our operating expenses increased to $2,094,044, for the nine months ended September 30, 2020 from $1,895,355 for the nine months ended September 30, 2019, for an increase of $198,689, or 10.5%. This change was primarily driven by an increase in legal fees of $677,646 and consulting fees of $259,773, offset by a decrease in stock-based compensation of $535,587, marketing costs of $180,354, and research and development of $156,911.

Our interest expense for the nine months ended September 30, 2020 was $388,143 compared to $47,858 for the nine months ended September 30, 2019. This increase was primarily driven by the Company’s promissory notes that were entered into during 2019, with an aggregate principal amount of $2,077,925, which it did not have during the nine months ended September 30, 2019.

Our foreign exchange (loss) gain was $(30,077) for the nine months ended September 30, 2020 as compared to $5,204 for the nine months ended September 30, 2019. The increase in foreign exchange loss is primarily due to the U.S. Dollar weakening against the Canadian Dollar and the conversion of the Canadian Dollars into United States Dollars for payment of United States Dollar denominated expenses.

The following table sets forth information comparing the components of net loss for the year ended December 31, 2019 and the comparable year in 2018:

Our operating expenses increased to $2,296,534, for the year ended December 31, 2019 from $1,919,577 for the year ended December 31, 2018, for an increase of $376,957, or 19.6%. This change was primarily driven by an increase in payroll and consulting fees of approximately $409,000, an increase in stock-based compensation of $117,896, offset by a decrease in patent costs of $652,624.

Our loss on extinguishment of notes payable increased to $32,316, for year ended December 31, 2019 was due to the Company entering into an amendment to the July 2019 Note on September 20, 2019, which extended the maturity date for such note to until the earlier of (a) the completion of a bridge financing of greater than or equal to $1.5 million, or (b) November 7, 2019.

Our accretion and interest expense for the year ended December 31, 2019 was $81,823 compared to $0 for the year ended December 31, 2018. This increase was primarily driven by the Company’s promissory notes that were entered into during 2019, with an aggregate principal amount of $740,336, which it did not have during the year ended December 31, 2018.

Our foreign exchange loss was $6,667 for the year ended December 31, 2019 as compared to $3,877 for the year ended December 31, 2018, for an increase of $2,790. The increase in foreign exchange loss is primarily due to the U.S. Dollar strengthening against the Canadian Dollar and the conversion of the Canadian Dollars into United States Dollars for payment of United States Dollar denominated expenses.

The Company has incurred continuing losses from its operations and as of September 30, 2020, the Company had an accumulated deficit of $7,377,068 and working capital deficiency of $3,589,158.

Since inception, the Company has met its liquidity requirements principally through the issuance of notes payable and the sale of its shares of common stock.

The Company has no present revenue and the Company’s ability to continue its operations and to pay its obligations when they become due is contingent upon the Company obtaining additional financing. Management’s plans include seeking to procure additional funds through debt and equity financings and to continue to develop its technologies under its sublicense agreement (see Note 4 to the financial statements for the year ended December 31, 2019). Without further funding, the sublicense agreement will have no commercial value.

There are no assurances that the Company will be able to raise capital on terms acceptable to the Company or at all, or that cash flows generated from its operations will be sufficient to meet its current operating costs and required debt service. Our ability to obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control. The COVID-19 pandemic has caused an unstable economic environment globally. Disruptions in the global financial markets may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets. Current economic conditions have been and continue to be volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business. If the Company is unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope of its planned product development, which could harm its financial condition and operating results, or it may not be able to continue to fund its ongoing operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern to sustain operations for at least one year from the issuance date of these financial statements. The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties.

On January 12, 2018, the Company entered into a sublicense agreement (which formalized the sublicense terms as agreed to in 2017) with TO Pharmaceuticals USA LLC (“TOP”). This agreement requires TOP to sublicense to the Company certain patent and other intellectual property rights for the exclusive use by the Company in cancer-related applications. These rights include intellectual property consisting of patents regarding cannabis pharmaceutical products. The sublicense does not provide for any ability for the Company to sublicense these rights to third parties without the express written consent of TOP. In exchange for the sublicensed patents, the Company issued to TOP 7,280,000 shares of its common stock along with an obligation to issue to TOP 40% of shares of common stock issued to investors during future financings up to $1.25 million. In connection with the additional rounds of financing, the Company issued to TOP an additional 2,157,162 common shares during the year ended December 31, 2018.

In January 2018, the Company closed a private placement for 1,900,000 shares of common stock for CAD $0.25 (USD $0.20) per common share for gross proceeds of CAD $475,000 (USD $376,203).

In October 2018, the Company closed a private placement for 992,244 shares of common stock and warrants to purchase 992,244 shares of common stock for CAD $0.87 (USD $0.68) per common share for gross proceeds of CAD $579,044 (USD $446,462). The warrants are exercisable immediately and expire on October 31, 2020.

On February 7, 2019, the Company received $60,000 in exchange for a promissory note to David Stefansky with an aggregate face value of $66,000, including an original issue discount of $6,000 (the “February 2019 Note”). The February 2019 Note bears no stated interest rate and was due on May 8, 2019. Given that the Company was unable to pay its obligation under the note, the February 2019 Note is currently in default. The Company amortized the full $6,000 original issue discount in the statement of operations and comprehensive loss through December 31, 2019. On December 30, 2020, the February 2019 Note was converted into the Company’s common stock in connection with the consummation of the Offer.

On February 1, 2019, the Company entered into a consulting agreement with David Stefansky. In connection with the consulting agreement, on March 5, 2019, the Company issued a note payable to its executive director for $150,000 (the “March 2019 Note”). The note bears no interest and is due and payable on March 4, 2020. The agreement expired on February 1, 2020. On December 30, 2020, the March 2019 Note was converted into common stock of the Company in connection with the consummation of the Offer.

During April 2019, the Company received $300,000 in exchange for convertible notes in an aggregate principal amount of $300,000 (the “April 2019 Convertible Notes”) and warrants to purchase 250,000 shares of the Company’s common stock. The April 2019 Convertible Notes payable bear interest at a rate of 6% per annum and are due and payable one year from the date of issuance. The notes are convertible at any time by the holder into shares of the Company’s common stock at a price of $0.60 per share. If the Company sells or issues common stock at a price lower than the conversion price of the notes, the conversion price shall be reduced to that price. The notes payable will automatically convert into shares of the Company’s common stock in the event that the Company consummates a reverse merger with a publicly traded company. On December 30, 2020, the April 2019 Convertible Notes converted into shares of the Company’s common stock in connection with the consummation of the Offer.

On July 8, 2019, the Company entered into a note agreement (the “July 2019 Note”) with a limited liability company (the “Lender”). The July 2019 Note’s face value was $157,714.29 and the original issue discount was $19,714.29 for total gross proceeds of $138,000. The maturity date of the July 2019 Note was September 8, 2019. As there remained an outstanding balance on the July 2019 Note at its maturity date, the Company was in default. Per the July 2019 Note, the Lender may at its option (a) declare the entire principal amount of the July 2019 Note, together with all accrued interest thereon and all other amounts payable hereunder, immediately due and payable; and/or (b) exercise any or all of its rights, powers or remedies under applicable law. In connection with the July 2019 Note, the Company issued warrants to purchase 131,429 shares of the Company’s common stock at an exercise price of $0.71 per share. The warrants are exercisable for a period of five years.

On September 20, 2019, the Company entered into the first amendment to the July 2019 Note. The amendment extended the maturity date for the July 2019 Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) November 7, 2019. In consideration for the amendment, the Company agreed to pay an extension fee of $18,926, which was added to the outstanding balance of the July 2019 Note. In addition to the extension fee, the Company agreed to grant warrants to purchase 50,000 shares of the Company’s common stock, subject to approval by the Company’s board of directors. If the Company’s board of directors did not approve the grant of the warrants prior to October 18, 2019, the Company agreed to pay an additional extension fee of $15,000 in lieu of issuing the warrants. On October 19, 2019, given that the Company did not grant the warrants, $15,000 was added to the face value of the July 2019 Note.

On November 21, 2019, the Company entered into the second amendment to the July 2019 Note (the “November 21 Amendment”). The November 21 Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) December 9, 2019. In consideration for the November 21 Amendment, the Company agreed to grant 25,440 shares of the Company’s common stock, subject to approval by the Company’s board of directors.

On December 9, 2019, the Company entered into the third amendment to the July 2019 Note (the “December 9 Amendment”). The December 9 Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) January 7, 2020. In consideration for the December 9 Amendment, the Company agreed to pay the previously outstanding extension fees of $33,926 on or before March 1, 2020.

On January 8, 2020 the Company entered into the fourth amendment to the July 2019 Note (the “January 8 Amendment”). The January 8 Amendment extended the maturity date for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) April 1, 2020. In consideration for the January 8 Amendment, the Company agreed to grant 50,000 shares of the Company’s common stock, subject to approval by the Company’s board of directors. On December 30, 2020, the July 2019 Notes were repaid in connection with the consummation of the Offer

On January 10, 2020, the Company issued a convertible note payable for $1,500,000 to Alpha in exchange for cash. On December 30, 2020, the convertible note issued to Alpha converted into shares of the Company’s common stock and shares of Series B Preferred Stock in connection with the consummation of the Offer.

The Company has no present revenue and the Company’s ability to continue its operations and to pay its obligations when they become due is contingent upon the Company obtaining additional financing. Management’s plans include seeking to procure additional funds through debt and equity financings and to continue to develop the Company’s technologies under the series of assignment and assumption agreements with Tikkun.

Based on the Company’s current development plans, the Company believes that existing cash, the cash it received from the Alpha Investment and this offering will be sufficient to satisfy its anticipated cash requirements for the next twelve months, but that the Company will be required to seek additional equity or debt financing in the next twelve months. In the event that additional financing is required from outside sources, the Company may not be able to raise monies on terms acceptable to it or at all. If we are unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope of its planned product development, which could harm its financial condition and operating results, or it may not be able to continue to fund its ongoing operations.

Since inception, we have primarily used its available cash to fund its product development expenditures.

The following table sets forth a summary of cash flows for the periods presented:

Net cash used in operating activities was $1,638,798 during the nine months ended September 30, 2020, which consisted primarily of a net loss of $2,482,187, offset by amortization of note discount of $285,858, increases in prepaid expenses and other current assets for $1,841, and increases in accounts payable and accrued liabilities of $522,162.

Net cash used in operating activities was $632,590 during the nine months ended September 30, 2019, which consisted primarily of a net loss of $1,975,470, offset by amortization of note discount of $38,985, increases in stock based compensation of $624,052, decreases in prepaid expenses and other current assets of $67,591, an extinguishment of notes payable of $32,257, and increases in accounts payable and accrued liabilities of $571,121.

Net cash provided by financing activities was $1,932,196 during the nine months ended September 30, 2020, which consisted primarily of $50,000 in proceeds from convertible notes payable, $1,812,410 in proceeds from note payable, $227,500 in proceeds from the sale of common stock, and a decrease of $157,714 in repayment of note payable.

Net cash provided by financing activities was $520,000 during the nine months ended September 30, 2019, which consisted of $300,000 in proceeds from convertible notes payable, $198,000 in proceeds from note payable, and $22,000 in advances from related parties.

The following table sets forth a summary of cash flows for the periods presented:

Net cash used in operating activities was $647,860 during the year ended December 31, 2019, which consisted primarily of a net loss of $2,410,673, offset by extinguishment of note payable of $32,316, amortization of note discount of 68,453, stock-based compensation of $624,052, increases in prepaid expenses and other current assets for $104,340, and increases in accounts payable and accrued liabilities of $933,652.

Net cash used in operating activities was $711,165 during the year ended December 31, 2018, which consisted primarily of a net loss of $1,919,577, offset by stock-based compensation of $53,294, stock issued for sublicense in the amount of $644,006, decreases in prepaid expenses and other current assets of $5,938, and increases in accounts payable and accrued liabilities of $151,668.

Net cash provided by financing activities was $560,000 during the year ended December 31, 2019, which consisted primarily of $238,000 in proceeds from notes payable, $300,000 in proceeds from convertible notes payable, and $22,000 in advances from related party.

Net cash provided by financing activities was $822,665 during the year ended December 31, 2018, which consisted of $822,665 in proceeds from common stock.

The Company did not have any off-balance sheet financing arrangements or liabilities, guarantee contracts, retained or contingent interests in transferred assets, or any obligation arising out of a material variable interest in an unconsolidated entity. Additionally, the Company does not have interests in, nor relationships with, any special purpose entities.

The Company’s accounting policies are fundamental to understanding its management’s discussion and analysis. The Company’s significant accounting policies are presented in Note 3 to its financial statements for the year ended December 31, 2019, which are incorporated by reference into this prospectus supplement. The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in the Company’s condensed financial statements.

Management does not believe that any recently issued, but not yet effective accounting standards, when adopted, will have a material effect on the accompanying financial statements, other than those disclosed below.

On February 25, 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). This update will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2019. The Company has determined that the adoption of this ASU will not have a material impact on the Company’s financial position and results of operations.

In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic, 842, Leases”, which clarifies how to apply certain aspects of the new leases standard, ASC 842. The amendments address the rate implicit in the lease, impairment of the net investment in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase options, variable payments that depend on an index or rate and certain transition adjustments, among other things.

In July 2018, the FASB issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements”, which provides entities with relief from the costs of implementing certain aspects of the new leasing standard, ASC 842. Specifically, under the amendments in ASU 2018-11, (1) entities may elect not to recast the comparative periods presented when transitioning to ASC 842 and (2) lessors may elect not to separate lease and nonlease components when certain conditions are met.

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. As of September 30, 2020, the Company did not have greater than $250,000 at any US or Canadian financial institutions.

From inception through September 30, 2020, the reporting currency of the Company is the United States dollar while the functional currency of the Company is the Canadian dollar. As a result, the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and the U.S. dollar.

The Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations in the future.

We are offering shares of our common stock and pre-funded warrants to purchase shares of our common stock. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. We are also registering the shares of common stock issuable from time to time upon exercise of the pre-funded warrants offered hereby.

We have authorized 120,000,000 shares of capital stock, of which 100,000,000 are shares of common stock, $0.01 par value per share and 20,000,000 are shares of preferred stock, $0.01 par value per share. On January 12, 2021, there were 11,595,109 shares of common stock and 1,775,407 shares of our Series B Preferred Stock issued and outstanding.

Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. Holders of common stock has no cumulative voting rights.

Further, holders of common stock have no preemptive or conversion rights or other subscription rights. Upon liquidation, dissolution or winding- up, holders of common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of the outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by the board of directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.

The holders of a majority of the shares of the capital stock, represented at the special meeting or by proxy, are necessary to constitute a quorum for the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of directors, which requires a plurality of the votes cast.

Our common stock is listed on Nasdaq under the symbol “ENVB.” The transfer agent and registrar for our common stock Corporate Stock Transfer, Inc.

The pre-funded warrants offered hereby will have an exercise price of $0.01 per share. The pre-funded warrants will be immediately exercisable and may be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise are subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our shares of common stock.

The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% (or at the election of a holder prior to the date of issuance, 9.99%) of the outstanding common stock immediately after exercise; provided, however, that upon notice to us, the holder may increase or decrease the such beneficial ownership limitation, provided that in no event shall the beneficial ownership limitation exceed 9.99% and any increase in the beneficial ownership limitation will not be effective until 61 days following notice of such increase from the holder to us.

At the time a holder exercises its pre-funded warrants, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrant.

In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction.

Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer.

No fractional shares of common stock will be issued upon the exercise of the pre-funded warrants. Rather, the number of shares of common stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.

There is no established trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to apply for a listing for the pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited. The common stock issuable upon exercise of the pre-funded warrants is currently listed on the Nasdaq Capital Market.

Except as otherwise provided in the pre-funded warrants or by virtue of the holders’ ownership of shares of common stock, the holders of pre-funded warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights, until such pre-funded warrant holders exercise their warrants.

In a concurrent private placement, we are selling to each of the investors in this offering Warrants to purchase one share of common stock for every one share of common stock purchased in the offering by each such investor. The aggregate number of Warrant Shares is 1,666,019. The Warrants will be exercisable at an exercise price of $4.9519 per share. The exercise price and number of Warrant Shares will be subject to adjustment in the event of any stock dividend and split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants.

Each Warrant shall be exercisable immediately upon issuance and have a term of exercise equal to five years from the date of issuance. A holder of Warrants will have the right to exercise the Warrants on a “cashless” basis if there is no effective registration statement registering the resale of the Warrant Shares after the closing date of this offering. Subject to limited exceptions, a holder of Warrants will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder prior to the date of issuance) of the number of shares of our common stock outstanding immediately after giving effect to such exercise, provided that the holder may increase or decrease the beneficial ownership limitation up to 9.99%. Any increase in the beneficial ownership limitation shall not be effective until 61 days following notice of such change to the Company.

We also entered into a registration rights agreement, dated January 12, 2021, with each of the investors, pursuant to which, among other things, we agreed to prepare and file with the Securities and Exchange Commission a registration statement to register for resale of all of the Warrant Shares.

Except as otherwise provided in the Warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Warrants.

The Warrants and the Warrant Shares are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying prospectus.

There is no established public trading market for the Warrants and we do not expect a market to develop. In addition, we do not intend to list the Warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system. All purchasers are required to be “accredited investors” as such term is defined in Rule 501(a) under the Securities Act.

We are offering 1,610,679 shares of our common stock at an offering price of $4.5018 per share and Pre-funded Warrants to purchase up to 610,679 shares of our common stock at an offering price of $4.4918 in a registered direct offering to investors that are not affiliated with us. We established the price following negotiations with prospective investors and with reference to the prevailing market price of our common stock, recent trends in such price and other factors.

The shares of our common stock offered hereby are being sold directly to purchasers and not through a placement agent, underwriter or securities broker or dealer.

We estimate the total expenses of this offering paid or payable by us will be approximately $1 million, which includes an advisory fee of $900,000 paid to Palladium Capital Advisors, LLC for its services as an advisor in connection with this offering. After deducting our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately $9 million.

We entered into a securities purchase agreement with purchasers covering the sale of the shares and pre-funded warrants offered under this prospectus supplement. A copy of the form of securities purchase agreement between us and the purchasers is included as Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on January 11, 2021, as amended on January 13, 2021. We currently anticipate that closing of this offering will take place on or about January 14, 2021.

The transfer agent and registrar for our common stock is Corporate Stock Transfer, Inc.

Our shares of common stock are listed on The Nasdaq Capital Market under the symbol “ENVB.”

The validity of the securities offered by this prospectus supplement will be passed upon for us by Haynes and Boone, LLP, New York, New York.

The financial statements of Ameri as of and for the years ended December 31, 2019 and 2018 incorporated by reference into this prospectus supplement have been audited by RAM Associates, CPA, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are iincorporated by reference in reliance upon the report of such firm given upon its authority as experts in accounting and auditing.

The financial statements of Jay Pharma as of December 31, 2019 and 2018 and for each of the two years in the period ended December 31, 2019 incorporated by reference into this prospectus supplement have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, which report includes an explanatory paragraph relating to substantial doubt about the ability of Jay Pharma, Inc. to continue as a going concern as described in Note 1 to the financial statements, and which report appears herein and elsewhere in this joint proxy statement/ prospectus. Such financial statements are incorporated by reference in reliance upon the report of such firm given upon its authority as experts in accounting and auditing.

We have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the common stock offered by this prospectus supplement and the accompanying prospectus. This prospectus supplement, filed as part of the registration statement, does not contain all the information set forth in the registration statement and its exhibits and schedules, portions of which have been omitted as permitted by the rules and regulations of the SEC. For further information about us, we refer you to the registration statement and to its exhibits and schedules.

We file annual, quarterly and current reports and other information with the SEC. The SEC maintains an internet website at www.sec.gov that contains periodic and current reports, proxy and information statements, and other information regarding registrants that are filed electronically with the SEC.

These documents are also available, free of charge, through the Investors section of our website, which is located at https://enveric.com/. Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus and you should not consider information on our website to be part of this prospectus supplement or the accompanying prospectus.

The SEC allows us to “incorporate by reference” information that we file with it. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus supplement and the accompanying prospectus, and information that we file later with the SEC will automatically update and supersede this information. We filed a registration statement on Form S-3 under the Securities Act of 1933, as amended, with the SEC with respect to the securities being offered pursuant to this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus omit certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits thereto, for further information about us and the securities being offered pursuant to this prospectus supplement and the accompanying prospectus. Statements in this prospectus supplement and the accompanying prospectus regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the registration statement, including the documents incorporated by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed above in “Where You Can Find More Information.” The documents we are incorporating by reference are:

In addition, all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed in such forms that are related to such items unless such Form 8-K expressly provides to the contrary) subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, before the date our offering is terminated or completed are deemed to be incorporated by reference into, and to be a part of, this prospectus supplement and the accompanying prospectus.

Any statement contained in this prospectus supplement and the accompanying prospectus, or any free writing prospectus provided in connection with this offering or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement and the accompanying prospectus will be deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying prospectus to the extent that a statement contained in this prospectus supplement and the accompanying prospectus, or any free writing prospectus provided in connection with this offering or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement and the accompanying prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement and the accompanying prospectus.

Upon written or oral request, we will provide you without charge, a copy of any or all of the documents incorporated by reference, other than exhibits to those documents unless the exhibits are specifically incorporated by reference in the documents. Please send requests to Enveric Biosciences, Inc., 4851 Tamiami Trail N, Suite 200, Naples, Florida 34103, Attention: John Van Buiten. You should rely only on information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus or any free writing prospectus provided in connection with this offering. We have not authorized anyone to provide you with information different from that contained in this prospectus supplement and the accompanying prospectus or any free writing prospectus provided in connection with this offering or incorporated by reference in this prospectus supplement and the accompanying prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or to anyone to whom it is unlawful to make such offer or solicitation.

•

whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;

•

a discussion of certain material or special United States federal income tax considerations applicable to the debt securities;

•

information describing any book-entry features;

•

the applicability of the provisions in the indenture on discharge;

•

whether the debt securities are to be offered at a price such that they will be deemed to be offered at an “original issue discount” as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of 1986, as amended;

•

the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;

•

the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and

•

any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations.

Conversion or Exchange Rights

We will set forth in the applicable prospectus supplement the terms under which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third party) that the holders of the series of debt securities receive would be subject to adjustment.

Consolidation, Merger or Sale

Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible into or exchangeable for our other securities or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.

Events of Default under the Indenture

Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:

•

if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended;

- 23 -

Table of Contents

•

if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended;

•

if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and

•

if specified events of bankruptcy, insolvency or reorganization occur.

We will describe in each applicable prospectus supplement any additional events of default relating to the relevant series of debt securities.

If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default arises due to the occurrence of certain specified bankruptcy, insolvency or reorganization events, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.

The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.

Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:

•

the direction so given by the holder is not in conflict with any law or the applicable indenture; and

•

subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.

The indentures will provide that if an event of default has occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series of debt securities, or that would involve the trustee in personal liability. Prior to taking any action under the indentures, the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or not taking such action.

A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies only if:

- 24 -

Table of Contents

•

the holder has given written notice to the trustee of a continuing event of default with respect to that series;

•

the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and

•

the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.

These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement.

We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.

The indentures will provide that if a default occurs and is continuing and is actually known to a responsible officer of the trustee, the trustee must mail to each holder notice of the default within the earlier of 90 days after it occurs and 30 days after it is known by a responsible officer of the trustee or written notice of it is received by the trustee, unless such default has been cured or waived. Except in the case of a default in the payment of principal or premium of, or interest on, any debt security or certain other defaults specified in an indenture, the trustee shall be protected in withholding such notice if and so long as the Board of Directors, the executive committee or a trust committee of directors, or responsible officers of the trustee, in good faith determine that withholding notice is in the best interests of holders of the relevant series of debt securities.

Modification of Indenture; Waiver

Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters:

•

to fix any ambiguity, defect or inconsistency in the indenture;

•

to comply with the provisions described above under “Description of Debt Securities — Consolidation, Merger or Sale;”

•

to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act;

•

to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;

•

to provide for the issuance of, and establish the form and terms and conditions of, the debt securities of any series as provided under “Description of Debt Securities — General,” to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;

•

to evidence and provide for the acceptance of appointment hereunder by a successor trustee;

•

to provide for uncertificated debt securities and to make all appropriate changes for such purpose;

•

to add such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or

- 25 -

Table of Contents

•

to change anything that does not adversely affect the interests of any holder of debt securities of any series in any material respect.

In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected:

•

extending the stated maturity of the series of debt securities;

•

reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or

•

reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.

Discharge

Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we may elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:

•

replace stolen, lost or mutilated debt securities of the series;

•

maintain paying agencies;

•

hold monies for payment in trust;

•

recover excess money held by the trustee;

•

compensate and indemnify the trustee; and

•

appoint any successor trustee.

In order to exercise our rights to be discharged, we will deposit with the trustee money or government obligations sufficient to pay all the principal of, and any premium and interest on, the debt securities of the series on the dates payments are due.

Form, Exchange and Transfer

We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures will provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement with respect to that series. See “Legal Ownership of Securities” below for a further description of the terms relating to any book-entry securities.

- 26 -

Table of Contents

At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.

Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.

We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.

If we elect to redeem the debt securities of any series, we will not be required to:

•

issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or

•

register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.

Information Concerning the Trustee

The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture and is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However, upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.

Payment and Paying Agents

Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest payment.

We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.

- 27 -

Table of Contents

All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.

Governing Law

The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.

Ranking Debt Securities

The subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.

The senior debt securities will be unsecured and will rank equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.

- 28 -

Table of Contents

DESCRIPTION OF WARRANTS

The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.

We may issue the warrants under a warrant agreement that we will enter into with a warrant agent to be selected by us. If selected, the warrant agent will act solely as an agent of ours in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. If applicable, we will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form 8-K that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of warrants that we sell under this prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.

General

We will describe in the applicable prospectus supplement the terms relating to a series of warrants, including:

•

the offering price and aggregate number of warrants offered;

•

the currency for which the warrants may be purchased;

•

if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;

•

if applicable, the date on and after which the warrants and the related securities will be separately transferable;

•

in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;

•

in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;

•

the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;

•

the terms of any rights to redeem or call the warrants;

- 29 -

Table of Contents

•

any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;

•

the dates on which the right to exercise the warrants will commence and expire;

•

the manner in which the warrant agreements and warrants may be modified;

•

United States federal income tax consequences of holding or exercising the warrants;

•

the terms of the securities issuable upon exercise of the warrants; and

•

any other specific terms, preferences, rights or limitations of or restrictions on the warrants.

•

before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:

•

in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or

•

in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.

Exercise of Warrants

Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.

Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to us or the warrant agent as applicable.

Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.

Enforceability of Rights by Holders of Warrants

If selected, each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.

- 30 -

Table of Contents

DESCRIPTION OF UNITS

While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.

We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form 8-K that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the terms of the units.

General

We may issue units comprised of one or more debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.

We will describe in the applicable prospectus supplement the terms of the series of units, including:

•

the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;

•

any provisions of the governing unit agreement that differ from those described below; and

•

any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.

The provisions described in this section, as well as those described under “Description of Capital Stock,” “Description of Debt Securities” and “Description of Warrants” will apply to each unit and to any common stock, preferred stock, debt security or warrant included in each unit, respectively.

Unit Agent

The name and address of the unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement.

Issuance in Series

We may issue units in such amounts and in numerous distinct series as we determine.

- 31 -

Table of Contents

Enforceability of Rights by Holders of Units

Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.

We, the unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. See “Legal Ownership of Securities.”

LEGAL OWNERSHIP OF SECURITIES

We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary or warrant agent maintain for this purpose as the “holders” of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as “indirect holders” of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.

Book-Entry Holders

We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary’s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.

Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.

As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary’s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.

Street Name Holders

We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in “street name.” Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.

For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.

- 32 -

Table of Contents

Legal Holders

Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.

For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.

Special Considerations for Indirect Holders

If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out:

•

how it handles securities payments and notices;

•

whether it imposes fees or charges;

•

how it would handle a request for the holders’ consent, if ever required;

•

whether and how you can instruct it to send you securities registered in your own name so you can be a legal holder, if that is permitted in the future;

•

how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and

•

if the securities are in book-entry form, how the depositary’s rules and procedures will affect these matters.

Global Securities

A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.

Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, NY, known as DTC, will be the depositary for all securities issued in book-entry form.

A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under “— Special Situations When A Global Security Will Be Terminated.” As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.

- 33 -

Table of Contents

If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.

Special Considerations For Global Securities

As an indirect holder, an investor’s rights relating to a global security will be governed by the account rules of the investor’s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.

If securities are issued only as global securities, an investor should be aware of the following:

•

an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;

•

an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;

•

an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;

•

an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;

•

the depositary’s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor’s interest in the global security. We and any applicable trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests in the global security. We and the trustee also do not supervise the depositary in any way;

•

the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and

•

financial institutions that participate in the depositary’s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries

Special Situations When A Global Security Will Be Terminated

In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above.

- 34 -

Table of Contents

A global security will terminate when the following special situations occur:

•

if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;

•

if we notify any applicable trustee that we wish to terminate that global security; or

•

if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.

The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we, nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.

- 35 -

Table of Contents

PLAN OF DISTRIBUTION

We may sell the securities being offered hereby in one or more of the following ways from time to time:

•

through agents to the public or to investors;

•

to underwriters for resale to the public or to investors;

•

negotiated transactions;

•

block trades;

•

directly to investors; or

•

through a combination of any of these methods of sale.

As set forth in more detail below, the securities may be distributed from time to time in one or more transactions:

•

at a fixed price or prices, which may be changed;

•

at market prices prevailing at the time of sale;

•

at prices related to such prevailing market prices; or

•

at negotiated prices.

We will set forth in a prospectus supplement the terms of that particular offering of securities, including:

•

the name or names of any agents or underwriters;

•

the purchase price of the securities being offered and the proceeds we will receive from the sale;

•

any over-allotment options under which underwriters may purchase additional securities from us;

•

any agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation;

•

any initial public offering price;

•

any discounts or concessions allowed or re-allowed or paid to dealers; and

•

any securities exchanges or markets on which such securities may be listed.

Only underwriters named in an applicable prospectus supplement are underwriters of the securities offered by that prospectus supplement.

If underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered securities if any are purchased.

- 36 -

Table of Contents

We may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus supplement for those securities.

If we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.

We may sell the securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.

We may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.

In connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the common stock for whom they act as agents in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional investors or others that purchase common stock directly and then resell the securities, may be deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions under the Securities Act.

We may provide agents and underwriters with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.

We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties (including the writing of options), or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction, the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others to settle such sales and may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement or in a post-effective amendment.

- 37 -

Table of Contents

To facilitate an offering of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons participating in the offering of more securities than have been sold to them by us. In those circumstances, such persons would cover such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment option granted to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of our securities.

Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is listed on The Nasdaq Capital Market. We may elect to list any other class or series of securities on any exchange or market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.

In order to comply with the securities laws of some U.S. states or territories, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.

Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of these activities at any time.

Any underwriters who are qualified market makers on The Nasdaq Capital Market may engage in passive market making transactions in the securities on The Nasdaq Capital Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security. If all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.

LEGAL MATTERS

The validity of the issuance of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter & Hampton LLP, New York, NY. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.

EXPERTS

The financial statements of the Company as of December 31, 2018 and 2017 and for each of the two years in the period ended December 31, 2018 incorporated by reference in this Prospectus have been so incorporated in reliance on the report of Ram Associates, CPA, an independent registered public accounting firm incorporated herein by reference, given upon their authority as experts in accounting and auditing.

- 38 -

Table of Contents

WHERE YOU CAN FIND MORE INFORMATION

This prospectus constitutes a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC’s rules, this prospectus and any prospectus supplement, which form a part of the registration statement, do not contain all the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statements made in this prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.

You may read and copy the registration statement, as well as our reports, proxy statements, and other information, at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The SEC’s Internet site can be found at http://www.sec.gov. You can also obtain copies of materials we file with the SEC from our website found at www.ameri100.com. Information on our website does not constitute a part of, nor is it incorporated in any way, into this prospectus and should not be relied upon in connection with making an investment decision.

INCORPORATION OF DOCUMENTS BY REFERENCE

We have filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended. This prospectus is part of the registration statement, however the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to “incorporate by reference” the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed. We have filed with the SEC, and hereby incorporate by reference in this prospectus:

1. Our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 26, 2019, as amended on April 30, 2019;

2. Our Quarterly Reports on Form 10-Q filed with the SEC on May 14, 2019 and August 14, 2019;

3. Our Current Reports on Form 8-K filed on January 25, 2019; February 14, 2019; April 2, 2019 and June 17, 2019; and

4. The description of our common stock contained in the registration statement on Form S-1 (File No. 333-220499) originally filed with the Securities and Exchange Commission (the “Commission”) on September 18, 2017, as amended.

We also incorporate by reference all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are subsequently filed by us with the U.S. Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of the offering of the securities made by this prospectus (including documents filed after the date of the initial Registration Statement of which this prospectus is a part and prior to the effectiveness of the Registration Statement). These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, as well as proxy statements.

Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement.

You may request, and we will provide you with, a copy of these filings, at no cost, by calling us at (770) 935-4152 or by writing to us at the following address:

AMERI Holdings, Inc.

5000 Research Court, Suite 750,

Suwanee, Georgia, 30024

(770) 935-4152

- 39 -

1,610,679 Shares of Common Stock

Pre-funded Warrants to Purchase up to 610,679 Shares of Common Stock

Prospectus Supplement

January 12, 2021

GRAPHIC 2 form424b5_001.jpg begin 644 form424b5_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH *2EIA)W@4GL ZD(I:#460,!TI:**T0!1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T@I,!:*** M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %&.:*0]* #-%-.!R:C,Z9QFA1)N39HS4"SKW-.\Y/6JY M6+F)M'FIZT6"Y)FC-1^:GK1YJ>M%@N29HS4?FIZT> M:GK18+DF:,U'YJ>M'FIZT6"Y)FC-1^:GK1YJ>M%@N29HS4?FIZT>:GK18+DF M:,U%YR9ZT>7^]7 F\DSC/%!O7]:/8A[0[_P#MY>FZD_M]>NZN M#6\?&2:8;U\X!XJ'2'SG?_V\H_BZT'7U'&ZN!-Y(5Z]*8M[(3SFI5(/:'H/_ M D"_P!ZC_A(%_O5P!O'R.>*7[6W3-5[(?M#OAX@4G&Z@Z^O]ZN -XX&0>:1 MKR3:",T>R$JAZ#_;Z]=U(-?7INKS];R0\'-.-XX'7FG[$/:'?'7U'&ZE_M]> MNZO/S>28!S2_;'SC/%'L1\[.^_X2!?[U'_"0+C[U>?&\ER>M+]KDV9[T>R#G M/0/^$A4_Q4?\) O][K7GXNY PH^UR;J/9"]IH=^-= XW4'703][I7!->OC.> M:47CXZT>R#VG4[W^WEQG=3X==6295W=:\]^VR9QGBI[&[D^U+SWJ)T[(J,M3 MV:SE\R%3[59K(T-R]FA/I6O7%)69UQ>@4445)04444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6D- F7,H\YJ]##)''58T,-V/6I6*A<5%MY)]*,YKTU M%'(WJ*I#,4'DY]* ,"GX&*.5#N-ZTW;@8-2< MTX@;?>LY0'=HC4@\>E*P!'% '3O2XYQ2Y!\S&!#M-1[3NQ4^<"DP.M'(*XP M+SGM3@0#@]Z>N"V*0KR::@@YG<,"F'EOI3^U.51M)I\J"Y&>.::3@8I_!ZT; M,C-+E0^9@""O3I0""*0C:..] P!3<4Q.3'8%'%':CM2Y$%R//.>U*3QCUIVT M=*55!!]J.4+C%]*GL"#>+]:BQWJ:Q %XGUK&K#0N#U/7]"'^@Q_2M:L?0C_H M:#VK7KR*NDCT:?PBT445!H%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !112&@&=6W)#C!J./ER:<%9W ZU+) 8AG%>A?0P7U*GS')H9MQP/QHY@L-_VJ/;UI<@H [T-2 M9[4^A-AV><4M,YZTN3Q[T!8=[U+8@BZ7W-1XJ2Q)^V+]:SFM"HNS/6]!_P"/ M)![5LBL?0A_H2?2M@5XE;XCT:/PBT445F;!1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:3O0)G,>*/FMB M/05Y9+\MP?K7JWB@ 6K'VKRB1@UV1VS7HX4XZL=31TV'S+E$Q]XUKZQIAM[4 M-BH_#]OOG5R/NFM_7E\RT"BNF*//(LDD8[U.ELR,21][I6S9:8C2\C MO6P^E1[5XZ4^8JQQ[P%!TJ%#YC;<5V4NF(R].:S(M*"W8PO&>:+A8Q6MF0;L M=:@$1=MM=G=:8OD\+5*STL,V2.]/F&HF;86A.5CD&MGPSAX&!ZTR^L"VH[@/XJERUL)(JS6 M>VQ+XK(>U:08'>NVO+3_ (ENW':J.G:>KAMXZ=*CFN-&#IT/DS"-AS6KJ5H% MM=V.U/>SV:EP*OZK$<1(!P1S2GCR\$5)IUD@EP16K?((8 M,KUHYM1VT.2O( N0!TK-:W(3=BNG6V$YR1]:L'2HVAQBK4K$M:G&>62*E2S: M1<@=*U9; I(1CO6QIVG*T)W#DBASL.*./\HDXQ3G@* $CK732:4J7'3BH-3L MUB@!QVIQF3)'..P1:=8M_I:'WIDF'&.].LP/MD8[9IS>A,=6>OZ"?]!C/M6Q M61H6/L,?TK7KQ:OQ,]*E\(4445F:A1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4G>EI.] F3H MI:](]Z]6\6Y^RGZ5YC:Q[KSGKFO1PNQRUCM/#T&(2:U;J'S5Q5+32(;4GVJS M;W*RR%2:VE?F,%L4TA^SOR*N>:)(_P#=I;V/]V6'6LZUF)$H/847OJ!8BN%D MGVU<6T"L&QUK"LW/]H>U=.'!C'KBE.ZV*16EVLK)@<"JUHJA6;'0TV>1HY&) M[TR-\6[$4TM (UG#7+J/6L+Q F7(JU8REM0DS_>J'Q.-J;EZUJMQ,?X8)W8] MZZ22)?M&X@\+@!=;!@".M7K>?S M(@Q/.*R=>A>9HO+&?6ICV8R[$HG N<<&IWC%T *6HRCYH@N\>AJ_].6=4.PU8 M)&WCI6)=RE;K"^M!)HM;"9MP%78(Q"N<4VR&8@3Z5/.,0.1V'%0WT+B4IY$: M? Q69KHW6W'85';/,]S\V>M7-1B\R +ZCFM(DR.#CXA"6IZ_H0_T&/Z5L5D:#_QX1Y]*UZ\>K\3.^E\(4445F:A M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 O2_%)_T<_2O*W.V[..E>CA=CCK' M6?VB([-AGJ*JZ=J?[_DUAO.[)MIT+^6F>]=CCU.=2.WDU-)8NHZ5C)>B.27_ M &JPTO90^,_+35N"9&)/TI* H7:L@8=Z@BO!]G*9KGGOGL?0T:Q= MBY.*R_,(D+#OUIEQ*6Y%:*)+D;.BW0A4BJ][<>;?<'H:H:=,5# GG/%0RRL+ MLD^M#B1S'6)J0@1]>5\D\U/);4:D=@K%:^#WN[WK-6]; 7/'>JTDI6 MXW#I2Y1N1Z)9W0,2@=Q5N64&+;7(:3?%G4,>*Z6XN(O(4J>>]9RBKEJ14D"P M2;^*BDO%9@/6L[4[\>9M5N*S([W]Z-Q[UI&)+9NWL2/;DX'2N3@^74A[-6S> M7Q%OP:QK?Y[]&]Z<]B5N>OZ$5'/GM7H88XJV]P M[TI'&:3G-+GM7J*-T<+8 =J:R\TO(HY-/E%S!M/6D53FG9I,XHY0N+]TTT6I0,"FHC4@S2&@#FI(HFD?:!18+W(8 1-GWI;GF7/J:L7$!@(.,53U+Y1=LYZ4]FW)CO3=S*M(:%D;8M(L9*;J15,AYZ5*6V?(>] M:*(-C"OR@48^;-*V12JDD.3SVZ4J$XJ>70%(LVL MWDMUZ5I_VB?+QNKGY"P;BG([XYJ'"Y2D6+B4O-C-0,2'4YIJ[FDR:DF7E::@ M-S)KEBUL.:;8+_I2#WI'/[@"EL<_:D^M95E9%0=V>OZ",6,8]JUZQ]!.;&/Z M5L5XM3XCTJ7PA11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% "&EHHH Y;Q7S;'V%>6LAACBK;V%!ZBD[T=Z*]>.QY[W%8YYH!P/K24Y>^:8AI]*0GBGX&* M3'- "1MCFEW_ ,/K2D 'BDQWIC2$#E9R>E MS2*+FM6N% ZBLZ/36:#..E=7>VXFVY':I8[.-;8#'.*PYR^0X'RF2?I5\:< M9(]V.HK:GTM3<9"\5>\B.&V(88XIJ8U XQO]&.P]J@D/F.'':KVI(&F)6JGR MA<5O!F;B'5<>M*&YQ M31UYI77H10!(A .:5VW&F=J6D,21_DVU-8M_I*?6H2N:FLN:#_P >2'VK9K(T+_CRCQZ5KUXE7XCTZ7PA11169H%%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2=Z6B@#F M/%A_T0CU%>5LNV9J]1\69^S'Z5Y9(3YQ]@JI+=^60/6K#SKA1GC%9=XRB53[US69L;4$8ECW&L+6[DQ#:!TK7A MG"QA0>U5+^U6X4DC-**=QMV.1#F4%B*IR*1)CUKH/L:QDC'%9-Y'LEKJAHC. M;1!T7'I3!\S9I31TZ5LM3!L.^/6E*9&*0YIQQ1T-!&>M(JX M8XIRKD9]*;SC%+DCBA@F&:EL5_TI?K4.#UJ6QS]J7ZUSU]C6F[L]>T'_ (\D M'M6Q6/H/_'C']*V*\2K\1Z=/X0HHHK,T"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH$SF/%7-J?85Y M4W^O8UZIXK.+;\*\NDQYQKT\+LCCK"#@_6EI%ZTM>JC@>XF:7-%% !1FBB@ MSQ0#QBE&.]-[XIBZC?O-]*OV4WDR!ZI8Q4@)"YJ&6MS:?5?G49ZU#M-GO6B,F-)R![4 X.:!UI6QFB0D M(:7.1BE&-M(.M*^H[" X.:#_ #IS8S0,8-*X6$S\N*EL&S>I]:AJ:QQ]L3'K M6%;8UI[GKVA?\>:'VK7K'T'/V-/I6Q7B5?B/4I_"%%%%9HT"BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2 MTAH$SE_%8_T4_2O+'7,Q'O7JGBK_ (]6^E>5OGSC]:]+#/1''6U%%'>C.:6O M33T.%K43'%&*7O13N*P=Z3%+11<=@ S3<9;-.YIG._VHYA6)".GO3CP-M-.1 MBG?>7WJ6QHC*[F!]*5CB@ TU@*@>/+Y]*DCSM]Z<5.,TGH) ML:(\C=1C;3T/K4;@^90F+H+1WI<4E7S"L.(P/K3<<4O-)S2<@L%'>E- I)]:A%3:?G[6N?6LJLM"X+4]=T(_P"AH/:M?-9&A_\ M'G']*U^U>+5^(].GL+11162- HHHI@%%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 (:*6B@1ROBQO\ 1OPKRUW_ 'I- M>K>*(C)!QZ5YC/9R?:#@<5V4)6.:JBL#@_6EWE=RJ:'+ MR%??QGTI=W'UJ?[%)CIQ1]CD Z57M Y"ONYQ1NXSZ58%G(>W-'V-_2CV@!]:7[$_7%-5 Y" M)I-H^M)YFY<59^Q.5Z4?87"=*?M$)Q*\;8&:5Y<#ZU.MH_I2?8G.E#64N. T&H$&[M1NYQ4_P!BDSTH^Q2>E+V@E'.'*0[N<5-8M_I:GWI?L4G/%/L+5_M:Y'>HG.Z*C$]9T' MFR0^U:]9&A*5LT!]*V*\VKN=M/8****S1H%%%%, HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM2M?/CQ7-O MX?!8\5VC*&'-1&%?2M(3Y3.<;G()X>'7'2G#01NSBNM\I?2CRESTK7V[,_9G M)'P^H&,=:0Z "!QTKKO*7TH\I?2CV[#V9R T *E=:81GI2^4N.E' MMF'L]3DAX?5AC'2C^P &SBNM6(#M2^2N>E'M@5,Y(^'EZXZTPZ ,8Q78^4OI M2>2N.E"K"]F-0G(IJOJ)TCBX=$#/LQUJU_PC MX/;I6Y;HOVD#%:7E+Z4Y5M05-LY#^P!G.*!X?&<8ZUUPA7TH\E<]*GVS'[,Y M(^'U'&*7_A'U/.*ZSRE)Z4>4N.E+VS#D.2&@#D8ZT'P^H&,5UOE+Z4IB4]J/ M;,?(2NZ_U=6:BG&8S1<5C)MF)N@:VAR* MQ[?'VP8Z5LCI3N"0WO2XI:*06$Q1BEHH'83%&*6B@!,48I:*!6$Q1BEHH'83 M%&*6B@+#6.*44$9I:7484444Q!1110 4444 %%%% !1110 4444 %%%% !11 M10 444A.* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-!.* %HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMU<")>M M6JPM:+^9A330%X7@V YH^VC'6L:&*9H^]/\ LMQL[T@-6.^# \]*=]L&!S6, MEK<9XSBGBUN,GKB@#7^V#=C-"W@)/-9'V6XV]\T&VN.,9]Z -G[6,=11]K7/ M45C_ &>XW=\4GV:YP>M(#8-VOK3!>#&M M'VP9QFLC[+<<]?:C[+]*XS9^V#=C M-+]L7GD5C?9;G'?-'V:Y]Z%N,V/M@V@YH-X,@9K'-K<^]'V:YV]\U3V$;'VM M<]:#> #K6.;:YP.M(UM<$]ZA"U-G[8,CGK1]L7?C-8WV:Y]Z/LUSG/-6,VC= M@*3F@78P.:QVMKD],TBVUR!SFIZ ;/VQ=^,T&[7!Y%8OV:YSGFG-;7)'&:8& MP+L%+N S6.EM]*]I<9R,TP-M*;P8'-9'V6XW=\4?9KCGK[4@-<7@W8S0+P<\UD?9;C;WS0 MUM<<8S0"-OM3$;/VI<=13!>#!YK(^SW.S&31]FN,CK2&:YO!M'- NQNQFLC[-<9/7 M%'V:XV]\TQ=39^UKZBC[4,=:QOL]SQUI3;W.[OBD!L&[7U%-%X"3S61]GN=I MZT?9KGCK3 US> #K3OM:X'-8QMK@MWI1;W.#UH UOM:E\9IQNE]16&+>YW=Z MD:WN,CDT#L:DUZJ ?,* MM9'V:X![XI/LMSSUH V/M@W'FD^VC!YK(^RW..^:/LMQGO3N!L?;!@<]:/M@ MW8S60+:XYSFC[-^*I ;7VI?44 M@NU)/-8XM[G;WI!;7(/>FK"-DW8"]:0W@!'-9/V:YSWQ2"VN,'K28(UOM@SU MI/MHQUK)^RW..^:/LMQGOBI8&M]L&,YH%V&XS64+6XYSFC[+^:$,UUNQ@ M\]*7[6N,YK':VN,#&:06]SWS0Q,V?M:YZTAO .]8WV:Z]Z7[-@#8^UCC MD4&['K6/]FNU9_D38[U'-;S&$]>E QEG> M#[7@GO6]]J 7.17&6]M/]IXSG-;@M[@Q]Z -878*YS2BZ7U%8J6UP#WIPM[G M!ZT :PO!N(S2F[ 7K6/]FN !US2_9K@MWQ0!K_:Q@^:.HC6^V#!YH^V# YK)-K<9'6E^S7&3UIA8UOM@W8S2"]'/-8_V6Y]Z/ MLMS[T ;'VT;]--K:3[:,9S60;6YQWI/LMS M[TD,VOMBY'/6G?:UW8S6)]FN?>E-M*#C-97V>XW=ZJ74=PIQDYI@=(MTNWJ*/M2XZBL&"*Y=! MR:E^SW.[O0#-@W8R.:4W:^HK%^S7/O2?9[GWI ;/VP;2C[ M-<^]5H,VOM8W8S2?:P03GI6-]FN?>E%MC[- M<[>^:-!,U_M@YYH^V#;UK(^S7''6E^RW&>^*&!KF\ (YH%X,GFLC[-<8/6C[ M-< #K4C-;[:,=:4W@XYK(^RW&[OB@6UQSU]J -?[8-V,T"\&#S6/]FN<=\TO MV:X]Z8C7-X-H.:/M@W8S61]FN,GK2?9KG'?- [FQ]L'/-'VP; ME^S7&[OBD!K?;!D:R/LMSCOFC[+<9'6F&IKF\&!S2_;!GK6/]EN,]Z/L MMQCO28:FP+P'/-'VH>M8_P!FN.,9I5M[C?WI7#4U_M0#=:8UZN[&X5E26]QM M/7-462X\P#)SFJ0'3?;!LSFC[8..>M8R6]P0.N*46UQSUHZ@;/VL;B,TGVP; M3S6/]FN<=\TOV6XSWI#-?[8,#FE^UC=C-8XMKCGK2?9KG'?- C8^V#GFD^V# M;G-9/V6XR.M+]FN-QZXI@:HO1G&:47@YYK&^RW.>]'V6Y]Z0S9^V#;G-!O%R M.>M8Z6UQGG.*0VUSGO0!L_;!NQFD%X#WK)-M<%1US1]FN-W>DQ&Q]K'K1]K' MK6/]FN=W>AK:XQWH%J:XO >]!O .]8_V:X]Z/LUQG/- &P;P;AS0+P'/-8_V M:YQWS1]FN..M S8^V#;G-.^UKQS6,;:XSWQ0+:YVGK1<9K_;!D\TGVP8ZUD? M9KG ZYH-K<]LTT(V/M@XYI?M8W8S6,+:YQWIWV:XV]\U0(US=C!YH%V,=:R# M;7&1UH%O<9/6D,U_M8W8S2_:Q@\UC_9KC;WS0;>XXZT :XNP5ZT?:QZUD?9[ MC=WQ2"&<9R30)FNEX&W6EV#TI]%(!FP=<4;!Z4^B@!FP8Z4NP9Z4ZBF S8/2C8,8Q3 MZ* &;!CI1L'I3Z* &;!Z4;!Z4^BE8!@0=<4;!Z4^DI )L'I2;!Z4^D!S5 -\ ML>E((QZ5)12L SRQZ4;!Z4^BF SRQZ4;!Z4^BD S8/2CRQZ4^BF S8/2EV#/ M2G44@&A!Z4FP>E/HI@,9!CI0JCTI]% %*[0;2,51LP#.5QT-:=UCRS6=9D&X M;'K0!K;!CI1Y8]*>.E% #-@]*-@]*?12 9L'I2[!C&*=13 ;L'I1L&>E.HH M9L&.E+L'I3J* &[!GI2;!Z4^B@!FP>E&P>E/HI6 9L'I1Y8]*?13 9L'I1L' MI3Z* &;!Z4;!Z4^B@!H0>E)L'I3Z* &;!Z4;!Z4^BD S8/2C8/2GT4P&;!Z4 M;!Z4^B@!FP>E&P>E/HH C\H;LXH*#IBI*3% &5J"C'3I4NG -%G%-U)@ *DT MT@Q<55M +NP>E1E QQBIJ3'.:D!OECTHV#TI]% #-@]*-@]*?12L S8/2C8/ M2GT4 ,V#THV#.<4ZEI6 ;L'I2;!Z4^BJ 9L'I1L'I3Z* &[!CI2;!Z4^B@!N MP9Z4FP8Z4^B@!NP>E&P9Z4ZB@!FP>E!C'I3Z* &;!Z4",#M3Z* &>6/2E*#T MIU% #0@]*3RQZ4^B@!NP>E)Y8]*?10!%Y(P1CK398AY)&.U3U%/GRC]*70#( MM8E^T9]ZV50;>E9%IG[5[9K9'2A -V#TI%49Z5)13 9L&>E+L&.E.HH 9L'I M2[!GI3J* &;!CI1L&.E/HH 9L'I1L'I3Z* &;!Z4;!Z4^B@!FP>E&P>E/HI M,V#THV#TI]%,!FP>E&P8Z4^BE8!FP>E&P>E/HI@,V#TH"#TI]%*P#-@]*-@] M*?10 S8/2C8/2GT4 ,V#TI#&/2I**+ ,V#TH$8':GT46 9L&.E9>H !LXK6S M67?LHE&>E B>P0>7DCJ*M^6/2HK3'E*1Z58IC&>6/2CRQGI3Z* &;!Z4;!Z4 M^B@!FP>E&P>E/HH 9L'I1L'I3Z* &;!Z4NP8Z4ZB@!FP>E&P>E/HH ;L&.E) ML'I3Z* &;!Z4NP8Z4ZB@!FP>E!0>E/HH 9L'I1L'I3Z* &;!Z4;!Z4^B@!GE MCTHV#TI]% # @]*-@]*?10 W8,=*38/2GT4@&;!Z4GECTJ2DS2L!%(@V$XK% M?BZZ=36\2-IK%E.3[H^E+0,84'I2[!CI3J* &;!Z M4%!Z4^B@!NP>E)Y8]*?10 S8/2C8/2GT4 ,V#THV#TI]% # @]*/+'I3Z* & M[!Z4A0>E/HH CV#THV#&,5)10*Q&$&E/HI6 9L'I M1L&.E/HIH!FP>E!0>E/HI@,V#'2C8,]*?10 PH/2@(,=*?10 S8/2FM"":EI MO>@1E7L C;=ZFK=B0(\57U0D*/K4NG ^3S2"Y?HH[44QA1110 4444 %%%% M!24M%)@%%%%- %%%% !1110 4444 %%%% !1110 E+3=W.*=20!12$@"F[J= MA-CZ*9NYHW#K3L+F0^BF;J-W.*+!S#Z*9NHW"BP*+"Y MD/HIFX&G9I#3 T445/48M(!BEHJ@"BF,23@4[.!18!:*;NI-W-.PN8?13-PH MW46%S#Z*;GBC-(=QU%)FF[N<46"X^BFD\4@.:+"YA]%,WC-&[G%.P*3=BBP#5M:"YM2[WI:8>M+FH&F.HIF[FC=18.8?13-W%&ZBP];0X%9-JN)\GUK5SQ3E&S$I#J*: M&S2;N<4K%*+#N.HIH/ M%&ZBP7T'44PMQ35.!S187,2TAINX&ES2L%[@1\M84H'VW&>];A/RFL"=&-_D M?WJN,1-G0)]P?2G5&I^0?2G9J;#N.HIA-&:+!S#Z*8#0318.8=2TT&C=BBP7 M'44S=2[J+#N.HIF>:-PHL+F'T4F>*;SNHL4/HI#TH7IS2 6BBB@ HIC [>*% MSCF@5Q])32V*,\4["EW46#F'T4S=1NHL',/HIFZC=18.8?13-U&\46#F0^BF;J-W-%@ MYA])D4FX4P@[J+%$M%%%( HHHH **** "BBB@!FW+9I)7V+FGU5OFQ;.?:E M4G8R+S61"Y7=57^WQ_>KBM>OI$NV4,:S1?R%?O&NN$$SFG,]'_M\?WJ4:^.F MZO.!?R#G<:/MT@.-QK;V*,_:'HYU\?WJ3^WQG[U><_;I/[QI!>RDYW&CV*'[ M1GH_]OC^]31X@RV-U>=F]EZ;C0+R7^\:/8H7M#T5O$ SNH7Q ,9W=:\Y-Y* M6^\<4[[9+C[QH]B@]H>A_P#"0?-C=Q3AX@_VJ\Z%Y)M^\U M9Z)_PD'^U5>76@\X.ZN'-Z^,[C47VV3=C<*3[?)C.XT>P0>T9Z/_;W'WJ3^WQ_>KSQ;Z3;]XTGVV3^\:7L4/VA MZ)_;_/WJ:WB#!&&ZUY^U[(3D,:07KX.6-'L4'M#T3_A(./O4Q?$&X\M7GWVV M39C<:/MK@C#&CV*#VIZ)_P )!_M4?V\.FZO.FOI ?O&F_;Y!_$:7L=1JH>C' M7QC[W2D&O@C[U>=B^D(^\::M_)N^\<5?L%87M+GI*Z\,XW"M:POA<]Z\?;4) M59HX&P:N"NS.;LAO]O_ #,-W2C^WQUW5YS+?2>:<,>M'V^3KN-=4:2L M82F>C?V\/[U!UX8^]TKSG[=)_>-'VZ3^\:KV*)]H>BKXAX^]2'Q#R/FKSO[= M)UW&C[;)_>H]BA^T/1O^$A_VJ3_A(!UW5YU]NDZ;C3?MTG7<:7L4+VC/23X@ M&/O4T>( /XJ\Y^W2X^\:/MLG3<:/8B]HSTF/70QSNI6UT+SNKS>/4),_>-$F MH2YSN.*?L4'M#T677 PQNJO'K0#GYNE<&E](RXW'-,^W2 GYCQ5*B'M#T8Z^ M/[U*=> 'WJ\X%](>=QI3J$@7!8T>P0O:O<]$_M\?WJ/[?X^]7G*W\A_B-+]O MDQG<:/8H/:,]%_M\?WJ<-=!_BKSC[?)C[QYIWV^3;C<.M!U"3.=QQ1[%![1GHK:Z!_%2?V^#_%7GGVZ0K]XTT7L MF?O&CV*#VIZ+_;X'\5-;7^?O5YZU[)G[QIC7TFW[QH=%#50]'BUP22!=U=': M3>=#NKQNROI#.@W=Z]8T.3S+)37-5C8WIRN:E+117.;A112&F R5]B$US=WK M7ES%2W0UNWQ(MFKR?6[]A?, W1JUIQN8SD=M_;_^U2C7A_>KS@:A)G[U+]ND MSC<:ZHTDSG<['HW]O#^]2_V\.NZO.?MTG3<:5;^3.=QQ3]BA^T/1_P"WAQ\W M6C^WANQNXKSC^T)!GYCSTI?M\FW&XYI>Q%[0]&_MX8)W4G]O #.[K7G/]H2= M=QI#J$F?O&CV(>T/2/[=&<;N*!KPP?FZ5YQ_:$F,;CFD&H29^\>.M+V(>T/1 M_P"WAMSNI%UT$_>KSP:@Y_BXI!?R#^(T*B'M#OKG6P1][I1;:_A/O5P+WSL, M;J([QP/O5?L>@B?V\- MN=U*=>&!\W6O-SJ$F.&.*4:C(!RQYZ4_8H/:'HXUT;L;J/[>'/S=*\W_ +0E MSC<&3\W2D_MX8SNKSHW\F/O&F_;Y,9W&FJ"8O:,]&_MX?WJ1M=&!\U>=&_D'\ M1YHDU%_+4;CG-$J*149W/7=,OA@M%%% M26%%%)F@"E>W'DH23TK".O!3RU3^)IS'!P<<5YA=ZE)YYPQQ753A='/.1Z1_ M;X_O4HUX9QNKS5+^7'+&E^WRY^\:OV*,G4/2/[?&,[J4Z^ ,AJ\W-_)C.XTJ MW\F.6/-'L1>T9Z-_PD _O4?\)!_M5YQ]NDZ;J5K]^H;I1[$?M#T;_A(/]JE3 M7QNQNKS?[=)UW&E^W2@_>-6J*L+VC/1FU\9^]TIW]OC9]ZO-_MTA_B-*NH2# MJQQ1[%![5GHS:Z!CYJ8^NAE^]7G9OY<_>-/-[(4^\:?L4'M#O(M: .[=4Y\0 M#'WJ\X%])L)W&D^VRE?O&IE1U#VAZ0FOC/WA2'Q -WWJ\W2^E'&XYH^W2[P= MQP*7L0]J>E?V\ =W6E.NC=C=Q7F[:A)UW'%+_:$F,;CFCV(>T/1QKPY^;I1 M_;XVYW5YM_:$G]X^]!U"3&=QQ1[%#]H>E?V^,CYJ/[?&3\U>:_VA)_>- U"3 M=]XT_8(7M3TC^WAC.Z@ZZ!CYNM><'4).NXXI/[0D_O&CV(>T/1SKPZ;J(==\ MR4#=7FYU"3.-QJ;3K^1KMM3UDZ*Q:U5CW%:M<4U M8ZHRN.HHHJ44%(QPI-+3)>(R?:F!BZCJGV8GFJ2Z^,9W5SWBN\:.=L'BN6%_ M+M/S'FNFG"YA*5CTDZ^"?O4?V\,9W5YPM])MQN.:47\G7=71[!6,'4U/1O[? M&?O4'7QTW5YS]ODZ[CS1]ME_O&E[%#]H>C?\) /[U']OC/WJ\Y^VRY^\:7[; M)UW&CV*%[0]&?7@.-U-_X2 ?WJ\Z-]+G!8TTWTI/WCQ1[%![0]'_ +?&<[J> MNO J3NKS7[=)C.XTY+^4(1N/-'L4'M#T6+Q #(1NJ"?6P9,[J\_2^D#?>.:= M+>R;@=QH]B@]H>AIKH"CYJ=_;P_O5YT+^0#[QYI/MTF<;C1[%![0]&_MX9^] M2C7^?O5YS]OD_O'BE6_?KNH]B@]H>C_V\-P&ZC^WAS\W2O-_M\N?O&G'4),< M,?>E[%#]HST;^WAMSNI?[=''S=:\X6_DS]XXI?[0D'\1H]B@]HST4:Z-Q&ZE M_MX!<[J\Y^WR8^\:0ZA(?XN*/8H/:,]$_P"$A_VJ/^$@']ZO.?M\@_B/-'VZ M3IN-#HH/:,]&_P"$@X^]5RPU7SY,9KRW[?)C[QKHO#MVSS#GK64Z:1I&5V>G M*)W:*!F!XQ51U$W M8BD\0;3]ZB'Q &;!:O.I+Z0RN-QY/%(M[(AQN.:Z(PNC"4K'I/\ ;XS]ZE;7 MQC[U>;?;I.NXTX7\F.6-5[)$\YZ)_;PQ]ZD7Q!DGYNE>>?;I.FXTT7LG/S4_ M9H.<]%;Q" /O4HU\8^]7FIOI2_WC3VOI0OWC2]D@YST8:_EC\W%#>(!CAA7G MGVR3R1ACFHDO9=V2QQ3]D@YST?\ X2#!'S=:KSE[V3'WJ5+^0Q[=Q MS2]DKASG?KXD)S\U0/K(\T-GJ:X=;MU.2:1[N1N0QJHTT'.>C_V\-OWA34\0 M@D_-7G)O9A%C<-'LD"FST2/Q&"<;OUI M[:\/[U>8)=S*_P!X\U:;4'V8W'-1[/4.=GH2>(0?XJ5O$&#][K7FZW*3IH.8])3Q M!N"C=U-=!:3^=&&KQJTOI#N*QFDC:,KFM12"EK(T"BBB@ M!KG:N:PM0UC[,V,UM3?ZLUYOXHN&CF(![UI"-S.;L;P\1;CC=4G_ D'&-U> M;I>2?WJ=]ND_O'BNF-),PE,]%_MX?WJ/[>']ZO.C?R==U'VZ3&-QK3V"(]H> MC?V\/[U'_"0#/WJ\Y^WR?WCQ2&^DZ[C4^Q0_:'I!U\#^*@:^#_%7F_VZ7^\: M/MTO]XT>Q0O:,]'_ .$@&?O4IU\8^]UKS;[?)UW4T7\N?O&CV*[![0]*&OCI MNI#KX_O5YLU_+T#&GO?R$#YC3]BA.H=_)K0;G=UI\>MA!C=7G\=ZYY+4CWTF M[ 8T_9:"H_MX?WOUKSK[?(?XCQ2'4)/[QI>Q17M#T<:^.FZ@Z^. MFZO.?M\@'WC1]MD(SN-'L4/VFAZ-_;XQG=0-?&?O5YR+Z0G[QH^W2#^(TO8H M/:'HQU\?WJ3^WQ_>KSK[=)TW&C[?(>=QH]B@]H>C?V^/[U(=>']ZO.OM\@_B M/-)]NDSC<::HH7M#TA=>!!^;I2?V\.NZO-QJ$F<;C3C?R8^\:ETDD5&=SU*Q MU7[3* #FMY3EDGTH@B)NQY!KHW7S&LX(.E:6K@G4&J@$->I M2CH>?4EJ-*#IZ4FW/-+M.<4['%=L8:&+EJ,P,_6E("G%-*L.:-K%?>DZ8H^>PFT#CUIH0;L4NTC)/>FG( ^M.4.P1GJ++%D@^E=WX.3 M &/2N*?[@-=KX,;YOPKSZ\3IIOJ=^O:GTQ>U/KSV=L=@HHHI%#,\FN7\5K_H M[&NGQS7,^*P?LC&MJ&LC";T/,)(QYC?6F;01BE9LRN/4T!2.*]6$-#BG*P8& M:-N*3!SFE((J^0SYQ@Z[:3^E28I,4<@ ME.VC&:848FG[2!1R"YQB@ FAQD4;"H.>]*B$C%/D%S,= .,FFD#S#[T[:5%- M"$')[T^0.8>$ .*1HPP^E&#TI,&CD#G&J@%/\L#CUI@!WTYP<4^0?, 0$X]* M0J O\ A_/V M!:\_$*R.VB;-%%%<1UA2&EI#TH!E6^&;9OI7C6M(/[3D'JU>RWO_ ![-7C>L M?\A5_P#>KIHJYRU7H4C$%-*%!&?2G.E/(+#%-*D<4>R%S! MM&U&P\^]'LD',(H XI=HSFF$$#'>G@%AGTJ5312D&T4H'&*3 M:0,TJ'Y>:KV8WX5Y>ZGS37J8:-T<=1C F/PI=HZTIY/':D"G<:[?9')*6HFT8Q2[?TH MVD+CO3E&,9H]D+F&[>WK4@(W4>M'LPYF-5!T-.VCK2-R@V]:;ALYI\F@ M:DTX 7BCU-,VGKVI]@C"\7/K6%6"2-:4KL]BT,?Z#'] M*U!65H7_ !X)]*U5ZUX]7=G?38^BBBLD;!3)?]6WTI]1R?ZMOI5(3V/+O&2C MSV%M&!TJ+# &D^;:*?(',/8# M.:0*.M&TGGM1L8?CTHY YQ-HZ4$ 8I=C8QWH\MF(]J' .8<$&-U-(!XIS*5% M,\MNG%/FN%'I6#(/W3#N>E;WA1"+@5RU8G3 M2>IZM!_JE^E2U#!_JE^E3#I7F/<[HO0****105RGB]O]$<>U=77(^,$9K1\5 M<-R)NR/,K9/.NF'H:N75IY0WXI^A6;27S?[U;^LZ<4BSBN^"1Q3.0QSCUI,< MX]*L+;,7([YJQ]@ M^Q,(NG-5H;=FEQCO1RH+BP(7PM37%LL*9J_:V#*VXCBHM7B81D#K3Y0N9$/[ MZ0KZ&M.+36QNVU7T:S:6?IWKM_)B@M0& S4N-F%SB+VW,/&*K1'(.>U=#J<* MR*=HK*6Q?:<"K41E &/K5N2R<76UDZ MRH<=Z]1T52MHH]JXJT;,WILUJ6D%+7,=*"BBB@8R0?NS7E?B]O\ 2&'H:]5? M[IKRSQU.D0J/K2Y YF."*$ZU&%!; M--.[;BE@!,GM3Y YA54;C2-&-V*4*1(WUHD4]*GV8C8QQ[4N0.<4@9H" #ZTF#OSVI^TYQ1R!S#2HQ] M*3 ZTK@@XI-I)SVI\@G(-@ZTFWDBEP>:7:=OO43A9&D):G1^$!B?\:]3@_U* MUY=X3XG'UKU&'_4K7EUU8[:3NB44M(!Q0*Y>IT+86BBBF 4444 %%%% "=JJ MWO\ Q[/[BK?:JE]_Q[/]*J&YG4V/(==/EZBV*SQ(:T/$ S>M]:S!T%>O01YM M1C]W.:3/:CI17:C$4'(^E-!(-&<&E+ 31&-W7M1(X5J06'!L BFB3)QV%-4$@^]!0XQWJD@ M)3)_%30_IWJ,(QIZH8_O=^E.R&AV,&EW \^E(ZEEXJ%0P-2Q,F#8_&DR>E)F MG<8J4Q,">*:1N%+25=M N*S$IBNX\%+D_A7#Y&TBN[\%^GM7FXE61U46=\HX MI:0=*6O*/104444#&FN6\5M_H;"NJ-8'B=C[T\MSFFO MS*<=C2YSS7N4U[IYM3<,XXHR3Q2&E)&![5=C(8Y('%("M(SE1Q3W.T<4@(:05+*6HU6/7UI/,).*60@/BDP ^.]"W"P!BW![4%BG M2G# -.P,Y/2G>P#02U(S'IZ4X$;2*8""V*8K KD\F@N0?8T'[W'2@D;".YI7 M&M1?>F;V+F]6QZTX8SFD) <5,EH5'< MEM>+I%]#7K^@\6*_2O(;0_Z6GUKV#0\&R7Z5Y&)/0H&K1117"=@4444 5+[_ M (]6KQO6?^0E(?1J]DON;9A7C>M?\A.3V:NO#G%B"D#^\W4[/;UI"1G-&:]> MFM#A8N>WI2J27IN>:<&&_-;6(8USAN*-WS8H8@')IH8&ANQ2'!B.?2G.?D#= MS1D&HF)SBDIHNP]9"1B@.2?I0B$+FC(Y]J$R6A2,MFA6"@CUIT?*[NU5^=^* M2 G9LKBF)G;3ATHR V*=PL(W7%(5&,"EE^4?6FQMD8-)L=B13E23VIM)G)I21U%42&:9U;'I3Q3#]['>L:FQK'<[_ ,&.709[ M&N]6N!\%D;/QKO5Z5X^(^(]"CL.HHHKG.@*0]:6D- FI>*N;4^PKRT\SFO4PNQPU=&+C'XT=Z#P:4D8KTT<4GJ(3FF,Q%/R-PH.,- M[TA)B1?/UHS\V*(F"KCO3::D"0[FDS\V*DC(933<98CTJXDM"[N] M .,^]"_>H)YIL2$).,5+8L3=+]:CXVU+8$&[3ZUS5WH:TMSUS0?^/&/Z5K@8 MK*T+_CRC^E:U>'4^)GITDN4****S-0J.0_(WTJ2F2?<--"9Y=XP&;HL:YS \ ML+ZBND\:'%TV*Y5"2N*]2A8X:K)(L*QC["G!LRD(.[?V%=JDYI=Q!VD4^/:6W-1,RF3 IW)L1AB>#VJ0K\F:BZ'-3HP(]JI6!(8#A2* M"Q*\=J)/N'%$3C9@]J L-63/)ZTT3%6^M&,OD=*<\6XC%2%B0-OICLPY Z4> M6T0YIPD0BD!'YA'XT;SG':D7EV_2G,.,=Z L/W9&?2H?..^GCI34CS)2N"0A M8^<%[&I';D"DD7;,,T$C>M5%W*:#)63%(Q.ZI)2=M- YJ48*X[TGJ-$.\E3[5TGA-RUV!7/$ "NB\(X M^VYK@KG523/4X1B-?I4@IL7W%^E/KRV>A'8****105RGC%BMBY%=77+>*QNM M6!JH;D5-CDO"Z$W18CJ:Z37E_P!'P!6=X>MO*9GQ6Y?H+B$@5W0;NCBDU06;QX8XJ5)BT*\$"[V0] MJQ=?C$8)%:YN +Q@/6LCQ&_[O=6JON'030(\-NQUJ75]1:.Y:/\ A%3>'0#; MEO:LKQ*A\TLO7--*[%++#I6K)?+'<^7VSB MIE>]@*4>G[KS;MXK2>P0*!CI6C"B'#@AJ5*[+M8S6T\>?G'4U M+J-DD$8 [BM&1D!#8[U5U3,SH%]*;NVA&0;?;%D"FP6(9A+CG-;$D %FF1VI MMLH\OI30(T[>,>4GL*GN8D^S[N*J>;Y2 'OTIMW.3: UE9ME:6*)C#AB.QI MMM9">1MXQBEL9 6Y]:TI2L:;EXS6FNQ)GW5@@3 JC;:<'FY'>M:)_..VKL-L M%^;%9R=@6Y5;3414('.:ZC3EV1 "L.:4+M!]:WM.<-$*XZIT4B[FG4F*6N8Z M4)2TE+0"&/\ =)KR_P 7G%P<=S7J+_<->6^+N+EL^M=.&U9A6.7493%*A/(I M%/RTN0!FO:I+0\Z;U!C3ATI 01FC/:K;$AI)Y]J3<0F:DXS0X!&1TJ;V!C8C MO.#3GX.!VJ((5!]ZD3Y@1W%',-(42$KGTIGF$'ZT]$(!)Z4U@ :JZ!C6D(^6 MB29F*@TO!:EE0;E(J&R;$C(!$&[FHT^3D4CR;5P:;R(ZI !D._-/5M_)ZTH4 M%,^E1H?WG'2ACMJ..2X7L:D;Y %]*:K /S393N88J;A8?N.3=J/4UZI$/W8%>6^$R/MB_6O4XON"O&Q.YZ-$?1117 M*= 4444 %%%% !1110 G:JM[_P >S_2K7:JM]_Q[/]*J&YG4V/(?$'%ZU9HZ M"M'Q!_R$&/:LT=*]BAL>;4W'8S112'[V:[49#G4<>]1S<#%.8'BHY 2X7WI2 M)6YHVMFTML3CM4'D?9W.1BNOT&S$EIR.U8WB"T,,QP,9-UL?+ MAR1VK"U)<7!7O3YA%53C&*&DPE-J6X/[]E':HJN.Q#6H8I0 >*2CI6O0D0BN]\%@=?:N"(XS7>^" MP>OM7FXO8ZL/N=Z.E+2#I2UY)Z2"BBB@!#7+>+!_HC&NI-(+,QS9 KF<];&BB<^2 M7F^AI6)\^M"STUY1NQ4CZ3(;C6R,5(=*CM[&27@4^8 M.4IJQW MZ=Y4)('056TVP,R[BM==/ MU&R*.U-L+);9-K"ESC<3F[S3]B<"LC[CE#VKO M+F!9(GP*X>\C*WKH.U;TWP:'Q9+]*\?M ?MB?6O8-"_X\E^E>/BCT*!JT445PG8%%%% %2^X MMF->.ZY_R$G]VKV*^_X]6KQO6O\ D)2#_:KLPQQ8@IX&_%+CFDP0:7O7KTMC M@:%*CK28&[%'>DPJ8+;\8X-:W]ERE1P<5 M832&5-Q%:J9+1E;@B[:8BY^8U)ATQHY@"*.8?*5FM=ZC(J6/33Y98+VK4E@";>*U[6W1[0MCJ M*3G;4I1.$2 F;:1WK=BTP/;$@=JC%K_II '>NELT6.,(PJ7-V'RG"&Q9+O!4 MUIKII\K.WK6]=Z:&N/,5>*LB-%14(&34\W431P\EJ89#D<4PD,,^E=#KMJ(H M=P%EQBM"$ IA^]FG$&F]&R:RJ;&D=SOO!8& MS\:[U>E<%X*!"?C7?+7C8CXCT*.PM%%%6GB8BO4PNQP5MQ3R:3H:#UI<=Z]-;'$P(P: ,]:2EZ$4^A-ACC; MS5RPM#/DXJK-S@UU7ANT#Q'(ZUE.5EK';BI MU^5,^M216C22@ =*M3V#I'TZTG(:@9R\RX[5/!"7=N.E3V^FR%>G-:=I8%0V M10I!RF5]A\V7I2WMD8(>!VK=LX +S!%6-15BZT MT^42%YK9TBV"P+D5IFW208P*7,/E.*M+)M^W;UZU;NM+\N/(%=(NGB&3>5XJ M:YA2:WP!S0IH?*<#&"@;/8T@(W$]S5O4(_)E(Z MWMU\E#CM7I4'9'#46IQMSIWES$@5'/;".$UU5[;KO)Q6'J,!\E@*Z^8R43 ! M.&QVJ.$/(^2*V+'37D1LCM5^RT8[\[>*%(3B8+Q%0,BHU."1VKHM1TUHUZ5E M)ILCG JE(5K%0'=$WK5<%E8 =ZOO9/%.%/2K::4SX;'6J3%8;:V(>+=BJ$K& M*Y"^AKL;&QVVNPCFL35-(?SMX'2IYKA;0S;MQY0(ZFGZ;9FX/3BJPI.5A)&)>:;]G3(%96"&KK=6EC?* =*PDLFFDRHXIM/#?+@]*O)8LW:EGTR1("<4N>X*)0(^7(J-9"#FM2+3W>'IVJ)=,??TJE+ M0?*5,[A70>$SB_Q6>VFND9)%:7AF(I?X]ZXZ[.BFK,]5B_U:_2I*9#_JE^E/ MKS6=RV"BBBD,*Y;Q0?D(-=37*^*D)B)%5#Q2LF2&S+9&<4ZROUF=E+=JY MB742ELT8;D#%5-/OVADWLW!KT(1NCAGN=IK-@(:5@3TIC:D&MFYZ MUFP7P$CE%K;!W6V/ ME^M37.GJ;GS/?-9LNH+%>#!QS6C/J<9M0>^*F2U T8Y52+ /.*P96SJ"\]6J MO'JH+DYXJN;U?M()3'O/:L8ZFKX7/>K=S?J+(D'M19 MBN:)*2PA0IQB#8",U+36@]!\Y5RO/2I&C1[4<\ MUSW]H8W$GI4T>JAHAS3<0N:4-NB9(/>II'!C()Z"LE-14(1FHI=3780#3L)% MZSE N.M=*F/)!'<5PME<[I@V:["SFWPXSVK&:*15NLF4#WKH=+!$0S6-(@,@ M^M=%9*!",5QU3>GN7**04MU2V/.FM15&!BCJJ1?<%>5^$P?MB?6O5(ON"O%Q.YZ5 ?1117* M= 4444 %%%% !1110 G:JM\?]&?Z5:[55O?^/9_I50W,ZFQY%K_-ZU98Z5I> M(#F^85F@Y ]J]BAL>;4W%IU)2$\XKL6QD.'S?A3$!>Y ]Z>&"U8T^W\Z\##I M2DQ):G<:.3#;*/451\00>8%/R[=1[5%JD7FVL2CJ#7#)^] M!Y3!>PKCM0S]N.?6NMTZ3S8W)YP*Y;6,?VF<>M:IZF9OZ1 &A ]:M7=B,=*- M&C*PKGTK4NMHC&142E:5AI&=96RXYJ'5+)7V[1GUJR7\E#)V%36N+E'8\TFW MN6D4K.P6.!215V\(&G/CL*2>=8X HJO*3)82-V I.[W$SB)P?M+-ZTRIKEAY MK"H,\XKIAL8RW!3S2T=!FEC8=:VZ$B9^7%=YX+)Z>U<$SU>=B] MCIH;G>CI2T@Z4M>0>D@HHHH 0URGBT9M6KJS7+>+/^/1A6U#XC&ML>6R+QU-8U#2.IVNC#R80/:J^M0^"U4W=B2T.AU!BX4>]#,T. MGLP'(HO%VJI/K2W4BR:>P4=JBYHHC-#N#/<%3W-7]6+6TAP.,5E>&XREZQ/0 MFMKQ"RE" .<5E*3YD.UD9EA<&XCDSVKDM4&S49#[UTNC_NA*6Z9KFMO8-#_X\E^E>/BCOH&K1117"=@4444 5+W_ (]F MKQO6_P#D)R>S5[)??\>K5XYK?.I/[-77ASBQ!2)).>]'>C(WY[4O>O8I[' Q M#G-.4DO02,4!@'S6I)'*=K?6MW006D''%84R$L#ZUU_AJUS$K8KEJZ&D3?F) M-@R>U8%O9*]R.U4OLICF9^U4BE:MZ3<&2S*^@J#5AG3UD]5S M4.@OFV)]J&[H=@LD,FHG(_BJ;4+HV]VB*>K8I=/=?MV['0U7U6W>34$D'3=F MI;=QVT.E@3S80Q]*YR^OC%J"IG^+BNFM'#6@0=<5QFL0M_:B..BMS1!ZNXFC M3UQ3)I"R8Y-<5 NT/]:[B_N$DT54[UQ!X#KW)K>DW8Q:%[YI2IA=C@K;BO29R,4[J M"*1C@8]*]),X7N)S2X)&:-P;D5(C!4?/<5?0$01?O)0E=]X=C\N#.*XC3(3- M=A:]$LD%O;@>U<=9Z6.B",W7(1.XSZU+8:>B1C@5:NK8RJ'[9I-_E0UBGIH4 MT"6D8D8G%5+^U4C('-3>=N!8'IUIMM*+J?':K3:U8TBG9Z8 ^<=:MW-B" ". ME:B*L745!<74;/M%3SML=BG'9I';ELI/YUJ&]!6#>DQZMY?>MJZ<);(I[BAM7!(CMB8K,,/2I--N3- M?6ID]!V-G4V,5LS>@XK-TRX:XA.:TO$3!;7 ]*R=!& MV$L>A%$'>-P.:\0-LO OK5,K^Y4U>\21F2\W"J#2 P(G<5V0,I+0**4F@'@U MHS$,\8J2P)-VOUJ*IK%A]K3ZUSU]C6GN>NZ$?]"C^E:]8^@_\>:'VK8KQ*GQ M'IT_A"BBBLS0*CF_U+?2I*CE/[IOI0)GF^J\ZQGO6_"/W$?N*PM5&-)$?!IX'DP;CTQ6>MV))<*:7-<4D/U.-7(%0VE@"-V*?/EI%K0C98+?> M:KFLK(BQAWFG!KM<"IC&L"8;C%7X)DG.X*C')INI 6T>!Q4.6MBT MBL;9))0>.*UU(@M!CTK(L"7.X]*O7DDT[F=AO]G MD"HI=/V=JZ2*$+\Y'%07:*$/%4I:C MT,."V4-@UH7%BK61(%01C,F!V-;(PUM@BB39*1CPV:I#R.HI(;1&DJW=N(H3 M]*@TPF5JKFT+L275@OV=B!T%9VC0^7?].];=W>1Q1E3VK)TRZ234CCUKEJMV M-('H,7^K7Z4X'FFP_P"J7Z5)7$SLCL%%%%(85RWBM]EHYKJ:Y#QGG[&^*NGN M9U-CS225GE;TS36;:@ I(V +@]33DB,AV=Z].F<,RPEP3%C-1*Y#$^M3/9O" MH)Z56W;6Y[UN02ARK9J(S,7)]*F"^8N!UJ)@$!SVIV M"\80XS42RL 354MG MYNU2HP^SMZU5K@A5G(=C3#*Q;=4JVC/$'%,R-VVA$D:%EDW5:.I2+P.E5_-4 M'9W/2DD38O/6@!9+AW<.>U74N3)"%S5($/'QVILE5YM1F>;!S4T5NRC<:ABWE.S!-, VHV>_2H/ M,P-@ZBCJ2V7FN,(2#5?SF:HT!>G)C+#TI/8I.Y/;71B<HZ"?]$7/>N* ML;4OB-<4M%%A]JMZ7'OG4 M^]5)>%^M;GAVU+.&(XK*3L4D=="-MECU%<[/;"6\Z< UU! \C8.I%9HM2)B2 M*YXOO2>4XP>M.,M=1VT M)KM0;+=Z"JFBW>)"N:M2_P#()#'NE8VBJQO6;M3W1-C9==]^I/K4&JW31,J+ MV-3O($NE!ZUG:G\\P^M2]QI&_IC&:SW'K63.Y MJ8N\FBI+0M:BWG:?NKB'4B9CZ&NUG<1Z2 W6N/ED5YB1ZUU4SGJ$#$YIU-8C M=4G08[UT=#!"4A.**#QS6<]C2.YTGA,G[8GUKU2+[@KROPD1]L4>]>J1?<%> M+B=STJ ^BBBN4Z HHHH **** "BBB@!.U5;[_CV?Z5:[55OA_HS_ $JH;D5- MCR+7@/M['O66 !6GKW&H,:S",K]:]B@>94%XHQDYI-A( ]*=TKM1D,8_, *V M=(PLX%8^P@Y/>KUA+Y]< \55B;FWI;JD+\]16!J"J^I9SWI\-[Y65SUJC=.3<[LU221+.ZT MU5%JI'85+?R#R5(-8>GZFJ6F">@I+G55:,#-0XN]REL6;B7-J1FI;"X$4)&> MHK"FO@8"N:5+T"#(/04-%)G23QK+:AAR2:5U6/39 3U%8]CJZ% &-)J6ICR& M53U%/E;T$SF[C_C[?T[5'CO3Y#Y@R.M-%;PV,9;@<8H48&*3!Y]Z$Y.VM>A+ MW&@9.37?>#>.1Z5P1&#FN]\%#O[5Y^*V.F@=\.E+2#I2UY!Z(4444 (:Y3Q= M_P >K5U9KE?%@S:L:VH?$8U=CR^0?O3[FI-HV8J-^)F^M2#YABO M( /FS3G&<4%?GS4H7Y":WYK$6&8 K4T50;@,>QK*1"\9J_ILOE,3Z5A-W-8H M["]U 00* >]6;:[6XM\9SFN)U*^,G0U:TG4_+A*L:YG!&QT%_M6/K5-9-MF3 MGG-4;_4UD /2H/MH^R]::0&YILJQL3GK6J\J2#&:XV.]VC@US<5 MF:==^4V,U])Q8D='J*+Y"^M16L*2VY4FJ-]J"LN,U7L=3"-M)[U M'+H4F:\*)9R%@<58F9+V+<3DU@:AJ0;[IJ"QU7:VTFI< N;LD$=M V#C(KA= M3(DO3Z UTFJ:D#!@'J*Y4DR2DUTTE9&;9*W)4^@IC4I^\#0>177?0Q>XJ =* M.]-4$"E YK*8+3BCOH&M M1117 =@4444 5+[_ (]6KQO6O^0FX_VJ]DO>+9C7CFMC&I2>[5UX8XL04B & MI:3!SBC'->Q3V.%AWH? H*]Z;*I*;>]:W(W9.H#A?:NOT2806HYKCH#L !K8 MANMD. >U8U(W-8(Z,:FINU3=U-:+2(T;'/:O.OMCK>!BQZUT U4&V'S=JY73 MU-T.F<&[SFI9MHEB(-8K7@,N_/%2F]W,ISTK5*PCITN!D FEO")(OPKFI-2" MD<]ZT%U-6@R3VJ.7J%[EZVQ$A.>U8>I2B2\&34KZHJC&>M9-W-NG#9I\H)G3 M7>V72U4G^&I]"M(ULLGN#6&][NM47/05>L]1$%F.:EQTL.Y.L:07AP>IJTZ+ M*V3VK!FO@TN0>M7+>_!0C/2AHJYL1W"0G;NYJ(V<5U)O;'6N9N-2/VW ;BM5 M-3$$')ZBERB(->9+:'RT/ KEH_FW,?6KNIWANYB >]4G^6/BMX:&,@_BIQ ' M2F*/D!]:7G%;HQZAC--/!SWIXIA^_FLJFQK$[[P6 $_&N^6N!\% A/QKO5Z5 MXV(^(]"CL.HHHKG.@*#110!RGBQ?]&_"O+SQ.17J/BKBU;/<5Y<>)B*]3"[' M!6W%)P:&P5SZTQE):G$';FO21PRW$7@8I7R$-(BG.*FD3,>*M/@U#:N,\U?+ MH%SL5G$@/-49E DS65;ZJN>M2OJ*L3S2Y;#N7+^4?867-9F@.J32DGOQ5>\O MA)&8P>352UN/L[$YH2$V:=Q&)M;WUNZE;J;5&]%KG;>[5KGS#6K?:FC6A7/. M*F4=5829/:JLMML/I1:QK:3[^G-8^GZHJMM)J;4=30+N4U+3*3-F_=;Q NT(8L8_I M6O61H1_T)![5KUXE3XCTZ7PA11169H%,D'R-]*?3)>8V^E GL>(V,6KY-3#4EVP@GH*]&BM#BJ;F]&8H8,[ANJF)A+O=6/ MVEE#<5>TJ4NTQ[5SC1^1<\5L^82@&>E8^I3+%)N-9QC9E M,L.1A35AY!):A,UB2ZBOE#GM1;:BI&":V43,NV[B#*DX)-5[VU$[JWJ:SKZ_ M OD(/%:"ZA&803CI6EA%J&)+>VV@]JS[.8FY?/8U7FU93E :KPW(5BV:$M26 MP\0*KD$=MG3+A(X!G&:;0D=+:11P!6)Q46J,MQP# MFL6_U<*$"G&*;;:D)'!)K)Q=[EW-:';;QXZ4MW,K6O6LO4KT)& #U%9PU#?! MLSTHY2N;0V=, D5C[TU$$>H9]6K.TG451CD]Z?+?*+O=GJ:?*3U<[>:J'C"@\U#-J/^C_ 'N@J5&PFS>LBDDG6M61DB3&:XO2M1Q, M235^_P!6&-H;FFXW!,M:A.&C;GH*BT*Y&_DUBSWN^(\]J9IMYY3[L\4^72Q5 M]3JM0C1X7;-96@1@ZF0>QILFI!X&7/6E\.MOU(X]:Y:VAI ].B&(U'M3Z9'] MQ?I3ZX#L6P4444# ]*Y3Q8 UHX-=4:Y/Q?G[$]:4]S*KL>7$?OWQV-;FC67G M2!B*Q8/GN&]C79:"JCG':O2I['!+<;JEK$L6..ENJGTTBW*@$ 2T QVK":(FZX'%=?>6A2 M$<=:I6VE%OF(HYD%CFY[4JPDQTJ4Q-+;!\WTDBU"D4NRMK,+;IQU%XI2=F-&#JM@&AZ5SD5EB7=CH:[^ZA$EOC'-9(TS]VSXZ&L^ M8902VW0].U9,]KMFZ<5UUI:$J1[5GZAIY#$ HK7.?V;QCTIHLR26Q6Q9 MZQZ'_P >2_2N*NC>EN:U%(*6N0ZT%)WI:3O0(1_N M&O*_%8_TQOK7J;_<->6>+!_IC?6NC#[F%8YJD P:"#NS1C/'K7LTMCS9[@B! MY3FGO&!(#WI%&SK06WON'2M&QQ"<\H*ZSP_M2 -GM7).A)!K9L+OR;?9GFLI MJZ&C?&IC[6$+=ZU"Z&/?GDBO/FN6^VAP> :W(]5S'MW5SN)JF79[D&XVYXJ* M9E+*,UIV^I M!@@)[4EL]ZSO$5P7D7Z5)-?*;@X/2LS4)O/N%JE$=]#?DE)TB% M?5.:CT*$"X.>F*I-?*MJD9[#%3Z;>I&U'+I8FYHW4:BY#'M4D]G')$LGK67J M.I+C<#TJ2WU='M4&:EQN-,V+:=+5=FX"HKB!+F42>AS7,:EJ168 -6I9ZB/L MX)/04U"VH7'ZPRI:; :X]0/,/N:U]6OQ+G!XK&CRS5M!&,V#@;Z>3DU$^=^/ M2GCFMTS$6C&>*3H:4=:SGL7#O5(ON"O&Q M.YZ5 ?1117*= 4444 %%%% !1110 G:JM\?]&?Z5:JK??\>S_2JAN14V/(-? MR;]AVK-'0"M372#?L*S0>17L4#S*FX[[JYJ,DE\"GR.,4MM"9'Q7;T,4)DG M-(',M0N.C>E'F\4[ 2R3M$NU> MAI@F=QS49?*T^,@+3:!,'D8QG'6D29MNP]ZDM\2/TILT?E29(ZFIY2TP=V@C M!6G1RM<1DMVICR"5=E1K*(N*M1N)L>"0Q%.%1JX+$^M2CD5:1F]Q#TI$X^;O M2YS^% /%:+8E[C3R:[[P6>WM7 @XR#7>>#.3^%>=BMCKH([\=*6D'04M>0>@ M%%%% "&N5\6'%HPKJC7*>+N;5JVH?$8U=CRZ4GSC]:D0D#--DYD/L:7.%S7O M4?A/-GN(3S2EB$--A4NV*LR6Y"?2G)ZD(B@.(3ZTP2,A..]20C)P*FDM&5E2*3$#BF#]VQIJ2B63 I-%BS2,<5)O;R,42 +C(ZT.X$> MVA1)N"R$I]*DAF9#FJZ^M2#J33Y1W))+EG;&:CAE+,X/:HU&'P:PJN+AT?- _P!::&7+9I84 MW#N>>]1 X.34A;*U: M5B&PC.X$T*3DT1_*A%**J+(!B0.*4&D)Q2@\42V&MQ]I_P ?J_45[#H1S9+] M*\>M#_IJ_6O8-!.;)?I7DXH[Z!KT445P'8%%%% %2_\ ^/5J\EL<+#.>*%RSTF>:V[0G;69I$:XRI?N*07+[0HIX8&*DMH"\F:5 MD;7T!W94I8)2P.>U274>WY:KI\AS4,B3'7#M@$=]([U$APW-%AIEEIF"@5,;AO("BJK$<>]*&XVT M]2T"9"\C&[W=JLRW3,@'I0EN97P!S M5>;]W)@]JE(&P7/WN]-!9Y@IZ5=M[8S(& X-2O9& 9(K6*(92;@[?2D%*Q^> M@D=:U,A"33>K8-/'-,/WL5E4V-8[G?>"B2G/K7?+7 ^"R"GXUWJ]*\;$?$>A M1V'4445SG0%!Z44'I0!R?BPG[,?85Y@>9CFO4?%?-J?85Y<>9R:]3"['!6W% MI.O%#-@X]:<,$?2O3MH<+W&Y*\T/*>!ZTA;>W%6(K)G(..M9MC16WLAS3I"9 MEY[5;NK,I'TJFAVJ<]JFUS9/0]*[C22-M.:9C:NVD "L']*7*3<:\KQ/E:D> M9YTP:7B4\#K3TC\I<,*31:D5X)GA+]:YJVQK3W/7-!_X\8S[5L5DZ%_QY1_2M:O%J?$>E2^$****S- J.0_NV M^E25')_JV^E-;B9Y=XO)%XS]ZYM;QR5]JZ/QB5]S M;N]7-,U)XI0">]5H(&GGV"K5QI89EV'DUG%78V]!S7$AB-+;W#K'GO2S*(XQD=JB#@QY%:\I-R5Y# M*=Y[5&+R3)7G J..8#*'J:?@=<4[$])!<6VF,;<5++.TAW&JH' MS8J?^#-58+ZC))FP ._6I$/]-S7'71M ]5B_U:_2I*CC^ZOTJ2O.9VQV"BBBD4)7+^*UW6CB MNIKEO%C^7:NQ]*TI_$95-CRM_P!S<-M[GFNAT*](DVD\8KGC^\G<^IK3TU&2 M; KTJ>QY\MSJGMQ>'/6K=K9"UY I-+&W!:K]W*H7BB3=[#1GWK!SM[5)"XCM M7)["LZ:X"'GUJ2Z<_P!GLP/5:NRM88ZVN!U)N[L58@8KYGO575D)M"0.U0&XS=# MGBKEVX>T^HJ^N@K'"V@(U'GUKT*U3-HK'L*X<(%U ?6NWCN%73A[+2FW8$BO M-= ,$SWJ2Y<16A'J*YF;4,W_ %XS6SJ$V;11ZK4-@6-/EW*:=,GG252TLGRV M.>U:-F0\W-4GU BC@$ /'WJN69RQ7MBF7^%=5'>GV2'?BDW=7%RCQ^ZDW=ZH M7UT7F4>IJ[>N!(,5CW2$3QMV)H6NI21IQPXP<<51UPC[*?4"M96 M@.^*Y[6 M9=T9'I0M6#.2MLB_5NY:O9-#_P"/%?I7CEN0;Y?]ZO8]#_X\%^EQ2V/-GHQ9"3R*2,,.W%6+: RC..M7'LC'">*N0XE$- MD'VJ..5M])G#E:DC WUG(:$&2V:B,[I+BK\=JQ/3K49M[TU$+B23R&0CG Z5/'M) / M-E HNH3%(OO3Y1>#Q2+US2Y MYK5$-68F"33AQ3N#@^E-9NQK,6,@\]Z]FAL>74W$/+<]*UM(C61QZYK-=?EQ6 MIX=4FY7ZUU2=D2D=4^GQ&&,C&X]:YK7K @\+Q76*I60$]*@U2))4Z"N12=S: MQQ(M'6V)V]!5:&V,C'CFNV6P$MJV%Z"LZSTW;>,".*$PL95EIK>8!MZU+?Z: M8QDK766MLD4Z@@4FLVJRJ@44U4M*PG"YP*63E]P6I3;LGWA@5UUMIRK$"5J' M5-+_ '!*CM5N:9/*7Y1FG7$+J0<E:0Q.6%6;O2LR A>!2Y]; HG M,+;2-#G;VJ".TD,F"IQ7;0Z:%BY7J*%TQ<$[13YT/E..>W"#D4PH%2M;5K?R MB2.,5D'E/K5WT$7]'MEED'I4VKV6)$"CO4GAR/#X/K6W=6PDE7([U-]2TKHY M%K)T^8+S4/V<-* U=P=-79G':L&73&-Z .YIJ:Z X&3)9,GW1Q3"/+/S<5V+ MZ<$MER!D5RFM)MF^6J4KDN)7(&,^M*@'X4T']R!W(H'$>.]:WT,I: WK7?>" MP,9]JX$C*YKO/!7'Y5Y^*V-Z#U.^'2EI%Z4M>0>F%%%% "&N4\6_\>C&NK-< MOXK_ ./5JVH?&95=CRU_]:<=SS3CM$>*:5/G2?6FR(2@4'O7O4=CS9Z,GTU0 MT_/K703V@^S%L=JP+7]W,AKL?+\[3E(]*FHR4CGM+M1+<[2.,UN7]C&MO\O4 M"H=)MMD_-7+AMS%?2L4]31(Y"XM7).U>:LZ5I+,^67O726VGAV+E>*T;&WC6 M3: *G0V[OR!Q6M_9C3(N/2M2TT\0P*&'-5S":L*D73Q% 2PZCBCGL)(Y%8B3M(J1[23;G:>*V8M/\ ,N>!6Q_9ZM#C M R!1S@T<*WRGGK3NX%6M4LS#=L>V:JJNY@*N^A#.GL[<26'(_AKGKBT-3B MCOH&Q1117 =@4444 5+[BV8UXYK7_(3?W:O9+W_CV:O'-;'_ !,W_P!ZNW"G M)7B4L#=BCO0X(.*0#/->K#1'G/<#2-Q2]Z1U+#;5REH%C<\/VJS.2>W2K.OZ M>(UWXJ7PY"8\,:T_$"B6UX%:?-:-&W M3BNPL-.40 E1R*K:G8@1' H4U<.4Y86[N.!TIAC:-SO&*ZG3+-9!@CI4&N:8 M5CWJ,4U-7'RF3IL0DN%7L:OZG:K$ <57T)?]*"GUK4\0C;$@%*4AN:D M"Y_"FMPK7!>"@0GXUWHKQJ_P 1Z%'8=1117.= 4&B@ MT H^*ABU;W%>6D'SR*]/"['!6 @%J<1M7ZTT+^\'M4L MZX4&O4OH<+$L[=I)QQP:["SL8UB!;TK+T6)74<:1;.4R E3UKKTTX-+TJ[_92[<[12=1=2E$Y_P"S(+(C MO62MNQD;CZ5T]S9-&<=JBMK$2R<#H::FB7#4Y6X1T?D5&Y^7%=+K6G^4I?%< MW(O45<9)D/0OZ1 LTF#6EJEBL465'.*IZ ,W&WTKH]1MO,P>V*B4K,:U./AL MG<,VWI58(ZW14BN]M-/583E1\PK&O-+_ -+X'>DIJY=C$EM96*MM-,N8ML2^ MO>NS6Q3R!D#@5S.L1>1)[9K:,DR)(SPN%I.#3T8%,5"5.[-:,A$HZ5+8@"[7 MZU$O(S4UDI^UJ/4USUEH;4SUO0O^/-/I6Q61H7%C&/:M>O$J_$>E3^$****S M+"HIO]4WTJ6F2\QM]*:W$]CRWQ8,W# UR\>%1C^5=1XP^6Z85RY'RC%>M1V/ M.JK4Z70+-9(UF8=:Z#4;2)[4A<=*S-!(-@@'6M?R6VX8]:N>XHLX&ZL&$[87 MBIK*Q;S066NL:P5V)QTIIME1<@"B+5RNASVKV@2)2H[15Q-.1@$VC(J7-"L M<4;)U3(4YJQ86Q63YAUKK'TU5;..*IR:>5DRHJ'*X^4KO8+(/E&:RKRP:$Y* MXKKK&V(FPU,UBU67 45'-K8.4XE;1VY J.2,K\F*[2UTL)#DKU%9L^CL]SD# MBJ4@Y3,L+,O(F1WK4UBU2*SSWK2M+$1% 1TJ'Q%$?LQ(JU*[2&XG&AA@J#71 M^$>+T^ES<5U)KE_%8_P!%>M*>YC5;L>7(NV=OK70Z.D;."YYK W#SV]C5 MF*Z,/Y&[5%;WRSL0[<5R\U\S+C=UJ*"^*-UK3E"Y MT>HF,#*GFHKF\4Z>4!YVUB3WY?G-5VG8H).V';BN/BN&\OK3UO'0X!-) MQN4=+)=1P7(*D=:OR7<E307S;.6-3R#YC>5X_/Y/>K=Y M/$+7 8=*Y5KI@W6EEN7DCQN-5:Q/,,$P:\SGG-;\]Z([$+GJMHW*&W78:D&N4^;H:TK>]C5=P8 M9-<%+_OU^T+AN*=-/$T,;%AD5R,MXS2O9-$_P"/-?H*X<0:T]&:H%'>E[45PL[ I*6D[TP& MO]TUY9XLQ]K;/K7J;_=(KRSQ<";IL=C73A]SGJ[',\$Y[TZ--\JIZU$@/6KE MG'F\C'J:]>GHCSI[G1Z=IZ+$"PP*LWD$/V=L$9J:?]S8J1Q@5SYU#S25SWJ6 MVWA2/EKH["T\Q"V/O4LNG;90<U36EMB3=ZUDY&BB4=3LTBTYA7&6EO(\TV%X!XKT#6(B M\!C'>LO3K%8]^Y1DTZ<]!2AJ<<+=A>'<*E>RDVDA3S71W>EXN/- X)K3CTU? MLW*CD5HYHS:Z'%PVCE#\O:HTLW5]S*>M=E%IZACQ3+K3P8BRBGSH%$S&MD^R M*1UQS64]J68@#BNB2W/DD'L*+2R#MC%-RL7RG(2VS(W(I8#RP/I73:OI_E1E M\=!7+QJ3*^*<9)DRB7=)17O@O:M;6;(*(V K-T*$B]&:ZC4(?,5!Z42>HE&Q MR?V.5CN"FJS(PE",.M=[9V*"WRRCFL>]T@F^5@.*A35[%*)A&U=8\[>*K 8^ M]UKL[BS5;55P,BN5U" I/Q6L))JY,HD7'&._6F/C.*6-#S43 ^9CTHF[HE*S M.F\(#_2U)]:]5B^X*\K\*\WB8[&O4HON"O&Q*U.^BR6BBBN4Z@HHHH **** M"BBB@ -5+[_CV?Z5;JK>_P#'J_TJH[D3V/(-=/\ Q,&':LP.<\UIZ\?]/85D M]6^E>Q0V/,J$TI/E9'6M/PN2;M0?6LW'[NM;PV MVH]ZWGL*)U]ZPAC4U1,Q MFCXYIFO782)5STJOHK_: #7,D[&MS=LUQ"0>]5X8P+V0]@*N ;%Q50G#R'VI M;L90FO2M^%!J>\N&Q&36$S%M97FMN_A/D1D=Q56$6?- M0^>*/,%Q 1UQ5"= MC'I(7/.:?I,F^-L]J0&O9PK%"6]JA#++N^M2&8>4RCN*SK=S'(8R>2YE8@]*[_ M %>V\\ #N*Y#4+$Q=NE:1>A'4O\ AQB9 ?>NL$>]@?2N4\.##!O0UU@E"(V> M]*39HG8KR78%V8<\5+]F!<28YK"8L^K$YXKI%<%5'M4O38=S!U746B+(#TKE MKAVNI"3S71ZOISO,[CH:R[>P* YK:%K$,RPAZ'MTH/IWJ>=@LY7WJ G]\36M M]#&2$).W%=[X*_I7"'[IKO/!1XQ[5P8EZ&]!:G>CI2T@Z4M>4>D@HHHH *Y7 MQ7_Q[M]*ZDUR_BO_ (]6K:A\9G4V/+_^6LGUIK-SCO3L_P"D-]:9(,39KVJ; MT/,J;BR.4=2*[31I?.LPI]*XR4?)73^&YL[4]*FHP1IA?LSD]*K6Y,\[?6KF MMD1&9V/K6*>ES1;FPH$,!SQQ698WQ:]QGO5O4IL0D"N>TMR;[KWH2 MNKFES5O9R]ZH_P!JH=8&$ %/N82MTK^IJ:ZMSMR;E^/#QKGTJ*_;$(5:U-MX_M,KK_= MI-VU&D,TZ#$!D8>,XK2F9;> H*R[6Q9+@S'H3FA.Y,C*\2QE9F M(KF[:0F8 ]A-CN-/_ ./$8[K5FU_=Q&JNF.!: M#/<5.[!8C4LM!!)]H=@>QJ5E$*N1Z50TIOW[DGO6G,-_F8[BDWJ)G'7MXQWK MGO64&8L2:UYM.O>'R39+FO(;+F[4>]>P:#_P >2_2O+Q)W89FO1117"=H4444 M5K[_ (]FKQK6R?[3D_WJ]EOO^/9OI7C>MG.I/_O5V88YJVQ3;YC3>1Q3@<-F MC(KU8/0\Z6XTT+DD>N:*FLE\V\4=J;V&CM='MRMJC8ZCFK=Y%YL>.U+#(MMI MX_W:9:7:W";:Y6W>YHB.U7R;=^QK/@G+7K#WK3N"$A8BN?L),ZFY]ZHUN;+D MB[7TQ5N64% A[TCP[Y!CTJO<1E98SGH:6YFQMW/]DA7!QS5B!1=0Y/-4M4MV MN(59?6K>G_Z-;8:A[70[]R>=EM84'2JEV#-;Y'-0ZQ/YB1[3T-6M/82VV326 MBU"Y!I<920@CO4VM(OV9OI5F"()(?>JNN<6K"B]Y:#.1T9B-2Q_M5K>)\B", MBL;1C_Q,P?\ :KI]:M?/MXR*TD]17*_AMS]E.:S_ "]VK,3_ 'JV=*MC#;;: MKM;>7>!_?-1YABW40N+0#K7-76F^2C<5<&!AKD] M:4DXS3V&TD>E1YXS70C.6XJDU&Y.X4_=S]::Y^85G5V""._\%?ZL?6N]%<'X M+.4'UKO:\:N_>/1I+0****P-@I#2TAH$SF/%7_'JWTKRPD^<3WKU+Q4'#N7WS5S5MWFQ M@=SS6=X;@N/6B]A-$/B"( M-:DUYW*6$K#WKT;63F#R^]U.3"*&7=P+=XD!ZU-]F$J^9CFL:_D,T\1!^Z:VK*Z7R ML'TK-II:%M&+J=ZULVT&N8U"9[H ]:ZG6-/:Y)9:PEL#&"&[5T4V9R,9=RBG MDDXJ>X0)DXJ"+YC6K>A%AWW>*GL2?M:'WJ"48XJ>Q8?:DK*IJC2&C/7=#_X\ MHSWQ6M6/H/\ QYH?:MBO$J_$ST:;O$****S+"F2_ZMOI3Z9+_JS]*:W$]CRO MQEG[2Q[US&3M6NH\8\W;&N8)PH]Z]6@]#@JG9>&E+0+GIBM.]NQ#QGFJ'AQ@ MMB/4"LG7;X_:N#P*TDKR,XG26\_F1%L]158S!IO+S5729=]KG/45%;N3JNS- M-*Q=S85AC:>],>TVGS .M074VRZB ]:V)&7[ ']JF3:)N4%(+#%6XQN7FJ&G M?OMP]ZTW'EICTJ9/H-$4LY2,J*AM1]YJ9(/,;(J>W7;&P]:6PQ\DJ^4P)[5P M&KG.H@KZUUE\653@UR=S\]\K&M8:".JC)_L5?]RN?TK<-1YZ5TUJ@DTT(/[M M9UM9>7U9-TY;4&P>]0]P-6XN0"!GK4B( M)$#5C7;$.HSVK:LV'V4>PJ7H%QH?RY..M0S2%YT!IKR@W'6GR1;2K46"Y>DQ M';+52-E8$]ZDG;?:A0>E9D+D7 7-);#+4LI21<53UR3=9\U;EA+.IJAKBE;/ M;5P"Z./+9#UT'A/_ (^Q7.$+_5K]*DJ.+_5K]*D MKS&=T=@HHHI#$KE?%I(M'KJC7*^+3_HCGVK2GN8U-CRYK16AP3>HW[QIKKMY% ?#$T[=NY]:Z%&QFI$7+<58"_NCGTJ$< M'%2A\C'I56&GJ5E7$F>]6%3S#BF'@[JNZ5'YLX'O2:&-\@HO(IJ0[N<5J:G& M(5'%16\127..:W-)L_W1XZ" ML[4L13FK21+9F[-Q:FJ,-CM4@<+GWIH89I-:DMBE/FS4AX48IC2 \TTR=/>F MHBN#%@,=JC0LS?2K.1LQ3(L D^E+E+3'6@(O5]F C_=->6>+,_:V]S7J3 M_=)KR_Q6?]+;ZUT4-S"KJ#BKNGM_ID>?6J1;YL58L7_TM#Z&O5IO0\^2N MSK]5+?V8"O7%<+:O*;[:0<$UZ&5%S9!>N16$NC^3<[B.])=BTC=TA/W: ^E7 M+V,*_%-LE"(GM4MZX)W5E)^\45WZJ!4\TOGS &JF MH2?963;W/-*S^1.K'TJ.^0W85EII";+T(6XM58U%?W?V:+:#CBBS;R+<(3R* MSM;!E *GI3MJ1(U8) ]@)NY%16C,8XV8GO328)V M-'R,))^E0Z?GS\5<\U71L4VR@_?[^U#>CN41>((A]B;'I7GV"DC5Z3JP\R I M[5PU[:%-QQ3I/04[,DT-LW(/>NMVAW0&N/T+BY!]ZZU9 '4UI)W)1--.()/+ MSQ5@QB2/S.X%8FH.6N00>];UL0;+/M6#T*V.?U6Z:/ 'K7-W?MB_6O4XO MN"O+?")'VI?K7J47^K%>9B=SNHDM%%%U5;X?Z*_TIQW(GL>1:YC[>Q[UE@"M/71_Q,&-9@'RGWKV<.KGFU!^\8Q5_ M1YO*G#$\@UE!26Q4\;&-@0:ZY1T,E*QJZU=^:.M/\/W@C8 GBL:5S+D$]:2U M9H6V@USN)HI:'>OJ28^]6>^HKO;YNM*C:9@V[)YHY+!S7-)YU74 M%?-;AODEB0%NE+#&?FZU@23--- MUXIAE93MSUHY1\QU,&IA[@J6XIU[M26]P0F :?(%SL%O$F?D]*R];5/*R.IK*LK MLAV)/0U+?S>;%UHY2+ZB:-.L3X)XS6O-J .0&KE(V:,\&I5N&<,<]*?*/F-R M"X7[1O)YJZNI 3+\W%M(LS>66R:7+M5%61-R&Y(-V?K3'P),TYP6ESZFFR+SBK9$F+U6N]\%@ M?I7!*/EKO?!8YS[5P8C8Z*+.]'2EI!TI:\L]%!1110 5RWBO_CU:NIKEO%8_ MT1C6M'XC.KL>7C_CX;ZTV3F4^E+_ ,MG'J:79R17LT]CS:FX9WI[BM31;CR9 MQS61;@EC]:?!(8YW.:&KD)G3ZS?"4X![56T^^$$3G-8CSM)U--1V\M\'I2C# MH6I=3IGOA/;DD\XK-TRX5+W)/&:SXYS'!R>O%1KNBR^?>J@HBO&BM-V>]2X:"4CI[[4U'RJW%6+2ZB:V4EA7%F9I M5+9/-2)?-%$J;CQ2Y1\QU%YJ"K(,-5BVO4@A:7=RPKC9[AI7#9J:2[:2V\L- MT%)QZ#N=!_:0N9_O9%:1O(DMC\PSBN"LYV@;#$YJRVH,_P#$>*.05SJ4=)8R M2>HKF]15$N ME17$C$9S1RCOH=#9WJQDD'K6I;Z@KLVYN,5QQ+1Q#GJ*>MTT<:_,:EQ%S:'3 M2SQC)R,UGWEPK1$ ]JRI+II.0:B:1BO)ZU:1#9&T8+$TU.AS4D?*XI@&2?:J M>Q)-9C_25QZUZ[H'_'FOTKR*R^6Z4GN:]>T 8L5KS<5L=N'W-BBDI:X#N"BB MB@"M??\ 'LU>-ZYC^TG_ -ZO8[[_ (]FKQO6QC4Y/]ZNO#G/6V*9Q0,8I&]* M2O5I['G3'5-9L(KE6J >M* 2>*U:T)3.CN-3S:[0W:H=)ORLN":PT9G+#/2E MAE,,'W;CQ3FO696&[K1RDMG66]Y'+" S#BJ]Y?JHVJU*:]VTPZTE#4.! M03TKAE8QOFKG]H$QXSTJI1N'.=7#=QK%C<,YIE[<1 *P(KDH[YB_4XHN+]G& MW)J>0.8ZRUU",KAF&*BU.>(P'!'2N46Y=5 W'BGSWC/'C-5&&H^KL73/0?!6/+&/6N\K@?!7$8 M'O7>BO&K?$>C2>@M%%%8FH4AI:3O0)G+^*N+4_2O+' ,Y':O5/%7%JP]17EC M#;,U>GA7H<59#N/*84V$@+2GD$4Q4(->HOA.+J6]/N/)N1@\5U=K>HX^9OI7 M$^64;.:N1W+*O!/%8RC<:9V=Y?QK:\,,U0M-15MPW<5S$]Z\D>-QI+61T1B6 MZUC[.QHF=3?/&(PX-16.HAW"LU8,M^9(A'GI44+,C;\U<8:% M*?+T#F.RNKA;B;KFJM\(X[!SGM6/#?$-N)I;^[\VV9 >HK2,2&RG9X$_F>]; MQU,2*%W]$197\PG@53BF-2-R6Z42(,]:G^W"(@!N*YMYFDDR#T MISRL5SFIY!N5SM(KZ.6'YF&:S+B6-G;::PX;A_+)W'BHDN6\ULGK6D(V,VR: M^V[B!5*/Y2:DE8N>M,*X /I6G**XYL-]:DLL?;$';-0+R=U3V0_TM?K6-31% MQ>IZYH7_ !YIZ8K7%9&@_P#'D@]JUQ7B5?B9Z%/86BBBLS0*9+_JS]*?3)?] M6WTIK<3V/+/&/_'XP'2N9P"!FNG\8C%RPKF N0IKU:"NCSZKU-[3+WR(-F>U M9NHN)9\YJ%6*DX-1Y+YKJ<>IDF;VG7*Q6Q&>@J.VN1]N\S/-8\4K#AK0FU3%ILW5R8E/F=>M.EF8@+FIY04CIM(O@C'<>IK M1O\ 4E$8VMUZUQD<[1D,#TI9+MI>-U0X:E)ZG46M^A3EJ5-242[=W4UR8G:, M;-QIHN',JMNZ4<@[G7:A<(T&0>37)22_Z3GMFI9-0+?*3561"3GUJXPL+F.N MTJ]7R-I;M4\ES&A+;AFN2@N&BVC-%W?L&QFFX"O&X-5'NU-V6)K% M\UB <]::69FZ]*AQ%*U)=07R5.[M7%RNWG8S5B>Y;8HW=!3Y0N=;%?H\6"U9TMVL=V"#Q6&E MXT<8.>M0S7#,NQLJDL*S=$A36"+QDA0[NU0S7+3+DFFH!< MA;&UC70>$\&[%IZS%_JU^E25%%_JU^E2UY;. MZ.P4444BA#7*^*\&T?/I75&N4\7<6;_2M*?Q&-38\O(_?/CUI GS9I8OGG?V M-.=MCUZU(\ZIN(54"G(%QS32A/XTA!''I7:EH8IDK!<>],&T'ZTS))W42H5 M/K3*6Q-(%V5?\.;6N@#ZUF(I>/%7O#Z%;Y?K6,]BT;GB.-0BD>M-TB%7MJ/$ M9(B3W-/T#_4;3ZUAS6T+3)8M.1YR6'>K8TY"_2K901J6]*;]I"Q[ZGG**-UI M<:H2!4-G:?O,$<5I?:5G^3UJ58A&,XZ4N=CL3BW1+?/>N;NK%;BZP!GFNAFG M_P!%+BL_3,2W#$^M2IM#L1IHT8MS\O:LZVTH;G)7H>*ZIY564Q>@J+RU2-FP M*<:@,@L;5$C(]JY/Q!&%O".U=1!=#SF7UKFO$?\ Q\DUI&3NV9R,0 =Z=M7\ M:C3Y^?2@Y!S70M49W'E5SQTI"H-)M.,4J<@^U4EH2R08V>]0IG<12H=QS3U7 M!-)EQ862XU!?J*]CT5LV:_05X];?\?:8_O"O7]$'^AH?85YF+W.NB; Z4E Z M4M>;U.T*3O2TG>F V3A#7EOBO_C[;ZUZE+RA%>5^*Q_I;>QKHH+4PJZ',,._ M>I8CYKBFN3\YSUI]M=L M$QN-*4+HI/0[/[6DY(+5CZNB",XZUF6U\4DR6[T7UYYJYSUJ81U)D]"+3)!' M<=>,UMR7@&.:Y6.0H^*L?:2_&>E:.()FS<7:E5.>*K7I_T5_I5FJ>H-BU<>HJH&,]CR?6L&_:L MLYQ6EK0Q?-6;Y@)SZ5[&'/.J;C=K#G'-'.X5,) 1G%1EOFQ7?=&0$$4B@YSW MIV_/X4OF#&:Y[HM)D9!)I^"1@]J X''K2[QT]*+H$@.2*,&CS!C=Z4>8!^-/ M0>HJC:U()>:7=\V* &$'D4HRJ<4[<.?:C M<-N: $4LG3O4AE=EP>E-W <>M.W#'3I1H38CP32$;>!WZT[S/FW49S^- AN6 M*[/X:0$A"M2<8Q1P:$,8"57 H (/'2G,0M"N,;:3:0:@<@4G)Z]:#("?I2-) MSFDY(5AQR%XKN_!).>?2N#$F5Q7>^"SQ]!7%B-CII+4[T=*6F(M*KCK06Y^M-%"PI[$E=M M-W=O2CS!U]*K0EASMVTT@D;/X:=Y@'/K1O'2C06HX JF!4>PMUJ02 _A2EP. M:AV+&$'(QTHY7\:=O'3UI"X)QZ4-(&-"DG)ZTFT@\5(7 .:0./SH"[%65U&W MM306SD]:4N.F*1I!C/I1H(&R30?F�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form424b5_002.jpg begin 644 form424b5_002.jpg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end

	Page
Prospectus Supplement
ABOUT THIS PROSPECTUS SUPPLEMENT	S-1
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS	S-2
PROSPECTUS SUPPLEMENT SUMMARY	S-3
THE OFFERING	S-7
RISK FACTORS	S-8
USE OF PROCEEDS	S-10
DIVIDEND POLICY	S-10
DILUTION	S-11
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	S-12
DESCRIPTION OF SECURITIES WE ARE OFFERING	S-19
PRIVATE PLACEMENT	S-21
PLAN OF DISTRIBUTION	S-22
LEGAL MATTERS	S-23
EXPERTS	S-23
WHERE YOU CAN FIND MORE INFORMATION	S-23
INCORPORATION BY REFERENCE	S-24

	●	the impact of the novel coronavirus (COVID-19) on our ongoing and planned clinical trials;
	●	the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed;
	●	delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials;
	●	the ability to establish or maintain collaborations on the development of therapeutic candidates;
	●	the ability to obtain appropriate or necessary governmental approvals to market potential products;
	●	the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms;
	●	our ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors;
	●	the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to our products, including patent protection;
	●	our expected use of proceeds from this offering; and
	●	other factors discussed in this prospectus supplement and the accompanying prospectus and the documents incorporated by reference herein and therein, including those set forth under “Risk Factors” in our Registration Statement on Form S-4 filed with the SEC on May 28, 2020, as amended (the “Form S-4”).

Product Candidate	Targeted Indications	Partner(s)	Status	Expected Next Steps
Cannabinoid-Infused Topical Product	Oncology- related skincare conditions (e.g., radiodermatitis)	U.S.-Based Center of Excellence	Research & Development / Discovery	IND submission; Exploratory Phase 1/2 trial with patient enrollment anticipated in the second half of 2020

Cannabinoid + Chemotherapy Combination Therapy Oral synthetic CBD extract given alone or in combination with clomiphene, concurrently with dose-dense Temolozomide chemotherapy	Glioblastoma Multiforme Recurrent or progressive	Dr. Tali Siegal, Rabin Medical Center, Davidoff Institute of Oncology	Research & Development / Discovery	IND submission; Exploratory Phase 1/2 trial with patient enrollment anticipated during the second half of 2020

Issuer		Enveric Biosciences, Inc.

Common Stock offered by us		1,610,679 shares

Pre-funded warrants offered by us		We are also offering the Pre-funded Warrants to purchase up to an aggregate of 610,679 shares of common stock to purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates, beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, in lieu of shares of common stock that would otherwise result in any such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each Pre-funded Warrant will be exercisable for one share of our common stock. The purchase price of each Pre-funded Warrant will equal the price per share at which the shares of common stock are being sold to the public in this offering, minus $0.01, and the exercise price of each Pre-funded Warrant will be $0.01 per share. The Pre-funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-funded Warrants are exercised in full. This offering also relates to the shares of common stock issuable upon the exercise of any Pre-funded Warrants sold in this offering.

Shares of common stock to be outstanding after this offering		13,816,467 shares (assuming all of the Pre-funded Warrants issued in this offering are exercised).

Offering price per share		$4.5018 per share of common stock and $4.4918 per Pre-funded Warrant.

Use of proceeds		We intend to use the net proceeds from this offering for working capital purposes. See “Use of Proceeds” on page S-10.

Concurrent private placement of Warrants		In a concurrent private placement, we are selling to investors in this offering Warrants to purchase up to an additional 1,666,019 shares of our common stock. Each Warrant will be exercisable for one share of our common stock at an exercise price of $4.9519 per share, will be exercisable immediately upon issuance and will have a term of five years from the date of issuance. The Warrants and the Warrant Shares are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying prospectus. There is no established public trading market for the Warrants and we do not expect a market to develop. In addition, we do not intend to list the Warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.

Risk factors		See the “Risk Factors” section of this prospectus supplement, the Form S-8 and in the other documents incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to invest in our securities.

Nasdaq Capital Market symbol		“ENVB”

	●	1,512,907 shares of common stock issuable upon the conversion of outstanding shares of Series B Convertible Preferred Stock;
	●	610,657 shares of common stock issuable upon the exercise of Series B Warrants;

	●	806,563 shares of common stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of $1.37 per share;

	●	547,805 shares of common stock issuable upon the exercise of warrants outstanding at a weighted average exercise price of $35.33 per share;

	●	2,695,893 shares of common stock reserved for future issuance under our Long-Term Incentive Plan; and

	●	1,666,019 shares of common stock issuable upon the exercise of the Warrants to be issued to the purchasers in a concurrent private placement with this offering at an exercise price of $4.9519 per share.

	Page
ABOUT THIS PROSPECTUS	6
RISK FACTORS	16
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS	17
USE OF PROCEEDS	18
DESCRIPTION OF CAPITAL STOCK	19
DESCRIPTION OF DEBT SECURITIES	21
DESCRIPTION OF WARRANTS	29
DESCRIPTION OF UNITS	31
LEGAL OWNERSHIP OF SECURITIES	32
PLAN OF DISTRIBUTION	36
LEGAL MATTERS	38
EXPERTS	38
WHERE YOU CAN FIND MORE INFORMATION	39
INCORPORATION OF DOCUMENTS BY REFERENCE	39

Offering price per share				$	4.5018
Historical net tangible book value per share as of September 30, 2020	$	(0.63	)
Pro forma increase in net tangible book value per share	$	1.14
Pro forma net tangible book value per share as of September 30, 2020	$	0.51
Increase in net tangible book value per share attributable to this offering	$	0.57
Pro forma as adjusted net tangible book value per share as of September 30, 2020, after giving effect to this offering					1.08

Dilution in net tangible book value per share to new investors				$	3.4218

	Nine Months Ended September 30,
	2020			2019

Expenses
Operating expenses	$	2,094,044		$	1,895,355

Loss from operations		(2,094,044	)		(1,895,355	)

Other expense
Extinguishment of notes payable		-			32,257
Interest expense		388,143			47,858
Total other expense		312,642			80,115

Net Loss	$	(2,482,187	)	$	(1,975,470	)

Other comprehensive income
Foreign exchange (loss) gain		(30,077	)		(5,204	)

Comprehensive loss	$	(2,512,264	)	$	(1,970,266	)

Net loss per share - basic and diluted	$	(0.10	)	$	(0.08	)

Weighted average shares outstanding, basic and diluted		25,916,419			25,060,193

	Year Ended December 31,
	2019			2018

Expenses
Operating expenses	$	2,296,534		$	1,919,577

Operating loss		(2,296,534	)		(1,919,577	)

Other expense
Extinguishment of notes payable		32,316			-
Accretion and interest		81,823			-
Total other expense		114,139			-

Net Loss	$	(2,410,673	)	$	(1,919,577	)

Other comprehensive loss
Foreign exchange loss		(6,667	)		(3,877	)

Comprehensive loss	$	(2,417,340	)	$	(1,923,454	)

Loss per share - basic and diluted	$	(0.10	)	$	(0.08	)

Weighted average shares outstanding, basic and diluted		25,085,980			22,607,147

	●	our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 25, 2020, as amended by our Annual Report on Form 10-K/A, filed with the SEC on August 12, 2020;

	●	our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, filed with the SEC on May 15, 2020, August 14, 2020 and November 16, 2020, respectively;

	●	our Current Reports on Form 8-K filed with the SEC on January 13, 2020, March 4, 2020, May 6, 2020, June 1, 2020, June 4, 2020, August 3, 2020, August 12, 2020, September 11, 2020, as amended by Form 8-K/A filed with the SEC on September 16, 2020, December 15, 2020, December 18, 2020, December 29, 2020, January 6, 2021, January 6, 2021, as amended by Form 8-K/A filed with the SEC on January 11, 2021, and January 12, 2021, as amended by Form 8-K/A filed with the SEC on January 13, 2021 respectively;

	●	the following sections from the Form S-4: “Risk Factors,” “Management of the Resulting Issuer,” “Information About Jay Pharma,” “Information About Ameri—Legal Proceedings,” “Principal Stockholders of Jay Pharma and the Resulting Issuer,” “Principal Stockholders of Ameri and the Resulting Issuer”, “Related Party Transactions” and “Description of Ameri Capital Stock;” and

	●	the description of our common stock contained in the “Description of Ameri Capital Stock” in the Form S-4.

Characteristic		Description
Mature Market	•	Most large global companies have already outsourced what they wanted to outsource.

Commoditized Business Model	•	North America and Europe continue to be the markets with attractive spending potential. However, increased regulations and visa dependencies prove to be a major drawback of the model.

	•	The benefits realized from the business model are largely based on labor arbitrage, productivity benefits and portfolio restructuring. These contours have changed due to commoditization.

Insourcing	•	Extremely rapid changes in technology are forcing IT services–traditionally an outsourcing business—to adopt an insourcing model.

Rapid Technology Shifts	•	Cloud services, robotic process automation, artificial intelligence and internet of things are increasingly in demand as part of outsourcing engagements. Smart robots increasingly operate in the cloud, and a ‘labor-as-a-service’ approach has emerged, as clients and providers find that intelligent tools and virtual agents can be easily and flexibly hosted on cloud platforms.

	•	Social media, cloud computing, mobility and big data will continue to be mainstays for any IT ecosystem.

	•	The convergence of cloud computing, virtualization (applications and infrastructure) and utility computing is around the corner. The ability of a vendor to offer an integrated basket of services on a SaaS model, will be a key differentiator.

	•	Enterprises are becoming more digital. There is a strong convergence of human and machine intelligence thanks to drivers like advanced sensors and machine learning. Operations and technology are converging.

Contracts & Decision Making	•	Large multi-year contracts will be renegotiated and broken down into shorter duration contracts and will involve multiple vendors rather than sole sourcing.

	•	The ability to demonstrate value through Proof of Concepts (POCs) and willingness to offer outcome based pricing are becoming critical considerations for decision making, Requests for Proposal (RFP)-driven decisions are increasingly rare.